<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">64944</article-id><article-id pub-id-type="doi">10.7554/eLife.64944</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>eNOS-induced vascular barrier disruption in retinopathy by c-Src activation and tyrosine phosphorylation of VE-cadherin</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-215982"><name><surname>Ninchoji</surname><given-names>Takeshi</given-names></name><email>nincho830@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-215983"><name><surname>Love</surname><given-names>Dominic T</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8530-1352</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-166607"><name><surname>Smith</surname><given-names>Ross O</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4239-3204</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-215984"><name><surname>Hedlund</surname><given-names>Marie</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-41846"><name><surname>Vestweber</surname><given-names>Dietmar</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-3517-732X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-22561"><name><surname>Sessa</surname><given-names>William C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-5759-1938</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-57798"><name><surname>Claesson-Welsh</surname><given-names>Lena</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4275-2000</contrib-id><email>lena.welsh@igp.uu.se</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Uppsala University, Rudbeck Laboratory, Department of Immunology, Genetics and Pathology</institution><addr-line><named-content content-type="city">Uppsala</named-content></addr-line><country>Sweden</country></aff><aff id="aff2"><label>2</label><institution>Max Planck Institute for Molecular Biomedicine</institution><addr-line><named-content content-type="city">Münster</named-content></addr-line><country>Germany</country></aff><aff id="aff3"><label>3</label><institution>Yale University School of Medicine, Department of Pharmacology and Vascular Biology and Therapeutics Program</institution><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Stainier</surname><given-names>Didier YR</given-names></name><role>Senior Editor</role><aff><institution>Max Planck Institute for Heart and Lung Research</institution><country>Germany</country></aff></contrib><contrib contrib-type="editor"><name><surname>Koh</surname><given-names>Gou Young</given-names></name><role>Reviewing Editor</role><aff><institution>Institute of Basic Science and Korea Advanced Institute of Science and Technology (KAIST)</institution><country>Republic of Korea</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>28</day><month>04</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e64944</elocation-id><history><date date-type="received" iso-8601-date="2020-11-16"><day>16</day><month>11</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-04-22"><day>22</day><month>04</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Ninchoji et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Ninchoji et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-64944-v2.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>Hypoxia and consequent production of vascular endothelial growth factor A (VEGFA) promote blood vessel leakiness and edema in ocular diseases. Anti-VEGFA therapeutics may aggravate hypoxia; therefore, therapy development is needed.</p></sec><sec id="abs2"><title>Methods:</title><p>Oxygen-induced retinopathy was used as a model to test the role of nitric oxide (NO) in pathological neovascularization and vessel permeability. Suppression of NO formation was achieved chemically using L-NMMA, or genetically, in endothelial NO synthase serine to alanine (S1176A) mutant mice.</p></sec><sec id="abs3"><title>Results:</title><p>Suppression of NO formation resulted in reduced retinal neoangiogenesis. Remaining vascular tufts exhibited reduced vascular leakage through stabilized endothelial adherens junctions, manifested as reduced phosphorylation of vascular endothelial (VE)-cadherin Y685 in a c-Src-dependent manner. Treatment with a single dose of L-NMMA in established retinopathy restored the vascular barrier and prevented leakage.</p></sec><sec id="abs4"><title>Conclusions:</title><p>We conclude that NO destabilizes adheren junctions, resulting in vascular hyperpermeability, by converging with the VEGFA/VEGFR2/c-Src/VE-cadherin pathway.</p></sec><sec id="abs5"><title>Funding:</title><p>This study was supported by the Swedish Cancer foundation (19 0119 Pj ), the Swedish Research Council (2020-01349), the Knut and Alice Wallenberg foundation (KAW 2020.0057) and a Fondation Leducq Transatlantic Network of Excellence Grant in Neurovascular Disease (17 CVD 03). KAW also supported LCW with a Wallenberg Scholar grant (2015.0275). WCS was supported by Grants R35 HL139945, P01 HL1070205, AHA MERIT Award. DV was supported by grants from the Deutsche Forschungsgemeinschaft, SFB1450, B03, and CRU342, P2.</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>retinopathy of prematurity</kwd><kwd>nitric oxide</kwd><kwd>retinal vasculature</kwd><kwd>vascular barrier</kwd><kwd>VE-cadherin</kwd><kwd>Src</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100012538</institution-id><institution>Swedish Cancer Foundation</institution></institution-wrap></funding-source><award-id>19 0119 Pj 01 H</award-id><principal-award-recipient><name><surname>Claesson-Welsh</surname><given-names>Lena</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004359</institution-id><institution>Vetenskapsrådet</institution></institution-wrap></funding-source><award-id>2020-01349</award-id><principal-award-recipient><name><surname>Claesson-Welsh</surname><given-names>Lena</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004063</institution-id><institution>Knut och Alice Wallenbergs Stiftelse</institution></institution-wrap></funding-source><award-id>KAW 2020.0057</award-id><principal-award-recipient><name><surname>Claesson-Welsh</surname><given-names>Lena</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004063</institution-id><institution>Knut och Alice Wallenbergs Stiftelse</institution></institution-wrap></funding-source><award-id>KAW 2015.0275</award-id><principal-award-recipient><name><surname>Claesson-Welsh</surname><given-names>Lena</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001674</institution-id><institution>Fondation Leducq</institution></institution-wrap></funding-source><award-id>17 CVD 03</award-id><principal-award-recipient><name><surname>Claesson-Welsh</surname><given-names>Lena</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R35 HL 139945</award-id><principal-award-recipient><name><surname>Sessa</surname><given-names>William C</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P01HL 1070205</award-id><principal-award-recipient><name><surname>Sessa</surname><given-names>William C</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>Merit Award</award-id><principal-award-recipient><name><surname>Sessa</surname><given-names>William C</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>SFB1450 B03</award-id><principal-award-recipient><name><surname>Vestweber</surname><given-names>Dietmar</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>CRU342 P2</award-id><principal-award-recipient><name><surname>Vestweber</surname><given-names>Dietmar</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Vascular leakage from pathological vessels in retinopathy aggravates the disease, but endothelial junction stability and barrier integrity can be restored by blocking formation of nitric oxide.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Pathological neovascularization is intimately associated with the progression of several retinal diseases, including retinopathy of prematurity, diabetic retinopathy, and exudative age-related macular degeneration. Neovascularization occurs in response to hypoxia, tissue ischemia, and the consequent production of angiogenic agonists, such as vascular endothelial growth factor A (VEGFA), a potent inducer of vessel formation and vascular leakage (<xref ref-type="bibr" rid="bib7">Campochiaro, 2015</xref>; <xref ref-type="bibr" rid="bib42">Semenza, 2012</xref>). The new vessels formed during retinal ischemia are often dysfunctional and fail to stabilize (<xref ref-type="bibr" rid="bib18">Fruttiger, 2007</xref>; <xref ref-type="bibr" rid="bib28">Krock et al., 2011</xref>), leading to vessel leakage or hemorrhaging and to retinal detachment, visual impairment, and even blindness. Therefore, suppression of neoangiogenesis, and thereby, retinal edema, is a therapeutic goal in the treatment of ischemic eye diseases (<xref ref-type="bibr" rid="bib13">Daruich et al., 2018</xref>).</p><p>A number of therapeutic options designed to neutralize VEGFA by preventing binding to its receptor, VEGF receptor 2 (VEGFR2), such as bevacizumab, ranibizumab, and aflibercept, decrease neovascular formation as well as edema (<xref ref-type="bibr" rid="bib30">Mintz-Hittner et al., 2011</xref>). However, they do not correct the underlying hypoxia; in fact, vessel regression may instead further aggravate hypoxia. Moreover, in many cases, anti-VEGF therapies can induce an elevation in intraocular pressure and hemorrhaging (<xref ref-type="bibr" rid="bib15">Diabetic Retinopathy Clinical Research Network et al., 2015</xref>). The repeated intravitreal injections of anti-VEGF-therapy present a potential for infections and scarring (<xref ref-type="bibr" rid="bib35">Patel et al., 2013</xref>); in addition, side effects including disrupted neural development in infants have been reported (<xref ref-type="bibr" rid="bib8">Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network Investigators et al., 2016</xref>). Thus, even though the current therapy improves vision for many patients in the early phases of disease, there is a clear need for developing new treatments to suppress proangiogenic stimuli while also achieving a long-lasting effect with safe administration.</p><p>Angiogenesis and vascular permeability in the retina are initiated by the VEGFA/VEGFR2 signaling pathway. VEGFR2 is found not only on blood vascular endothelial cells but also on neuronal cells in the retina, likely contributing to the side effect of VEGFA/VEGFR2 suppression on neural development in premature infants (<xref ref-type="bibr" rid="bib32">Nishijima et al., 2007</xref>). VEGFR2 activity is initiated through VEGFA-induced receptor dimerization, kinase activation, phosphorylation of tyrosine residues in the receptor intracellular domain, and activation of signaling pathways. The VEGFR2 phosphotyrosine-initiated signaling pathways are now being unraveled. Phosphorylation of Y1212 in VEGFR2 is required for activation of phosphatidyl inositol three kinase and AKT (<xref ref-type="bibr" rid="bib49">Testini et al., 2019</xref>), while phosphorylation of Y949 is required for activation of the c-Src pathway and regulation of vascular permeability through vascular endothelial (VE)-cadherin (<xref ref-type="bibr" rid="bib29">Li et al., 2016</xref>). VE-cadherin is the main component of endothelial adherens junctions, strongly implicated in regulation of vascular permeability, leakage, and associated edema (<xref ref-type="bibr" rid="bib21">Giannotta et al., 2013</xref>). In particular, phosphorylation of the Y685 residue in VE-cadherin correlates with VEGFA-induced vascular hyperpermeability (<xref ref-type="bibr" rid="bib46">Smith et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Wessel et al., 2014</xref>).</p><p>Endothelial nitric oxide synthase (eNOS), activated downstream of VEGFA through phosphorylation on S1177 (S1176 in mice) by AKT (<xref ref-type="bibr" rid="bib20">Fulton et al., 1999</xref>), produces nitric oxide (NO) and regulates vascular permeability. Both mice with a constitutive eNOS gene (<italic>Nos3</italic>) inactivation (<xref ref-type="bibr" rid="bib19">Fukumura et al., 2001</xref>) and mice expressing an eNOS serine to alanine point mutation (S1176A) (<italic>Nos3<sup>S1176A/S1176A</sup></italic>) (<xref ref-type="bibr" rid="bib14">Di Lorenzo et al., 2013</xref>) show reduced extravasation of bovine serum albumin in the healthy skin in response to VEGFA challenge. An important mediator of the effect of eNOS-generated NO is the relaxation of peri-vascular smooth muscle cells (vSMCs), leading to increased vessel diameter and enhanced blood flow and thereby flow-driven vascular sieving (<xref ref-type="bibr" rid="bib43">Sessa, 2004</xref>). In addition, eNOS activity correlates with tyrosine phosphorylation of VE-cadherin in cultured endothelial cells (<xref ref-type="bibr" rid="bib14">Di Lorenzo et al., 2013</xref>), providing a mechanism for how eNOS activity may directly affect vascular permeability, distinct from vasodilation.</p><p>In contrast to the skin vasculature, the healthy retinal vasculature is protected by a stringent blood-retinal barrier. In retinal diseases, the barrier is disrupted, leading to increased vascular permeability (<xref ref-type="bibr" rid="bib56">Zhao et al., 2015</xref>). In accordance, NO and related reactive oxygen species (ROS) are important pathogenic agents in retinopathy (<xref ref-type="bibr" rid="bib33">Opatrilova et al., 2018</xref>). However, the molecular mechanisms whereby eNOS/NO interferes with the retinal vascular barrier and contributes to pathological vascular permeability in eye disease have remained unexplored.</p><p>Here, we show that suppressed NO formation via the use of the competitive NOS inhibitor, Nω-Methyl-<sc>l</sc>-arginine (L-NMMA), which inhibits NO formation from all three NOS variants (eNOS, inducible NOS, and neuronal NOS), or an eNOS mutant, S1176A, negates neovascular tuft formation and vascular leakage during retinal disease. Mechanistically, NO promotes c-Src Y418 phosphorylation at endothelial junctions and phosphorylation of VE-cadherin at Y685, required for dismantling of adherens junctions. Inhibition of NO formation by L-NMMA treatment suppresses vascular leakage also from established neovascular tufts, separating regulation of leakage from the angiogenic process as such. Mice expressing a VE-cadherin tyrosine to phenylalanine mutation (VEC-Y685F) are resistant to eNOS inhibition, supporting the model that NO regulates adherens junctions through direct effects on c-Src and VE-cadherin. These data suggest that eNOS/NO promote vascular permeability not only through the established effect on vSMC relaxation and increased flow-driven permeability to solute and small molecules in the precapillary arterial bed, but also through disruption of adherens junctions allowing leakage of larger molecules from the postcapillary venular bed.</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Strain; strain background (<italic>Mus musculus</italic>)</td><td valign="top"><italic>Nos3<sup>+/+</sup></italic> (C57BL/6J)</td><td valign="top">DOI:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bbrc.2012.12.110">10.1016/j.bbrc.2012.12.110</ext-link></td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Strain; strain background (<italic>Mus musculus</italic>)</td><td valign="top"><italic>Nos3<sup>S1176A/S1176A</sup></italic> (C57BL/6J)</td><td valign="top">DOI:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bbrc.2012.12.110">10.1016/j.bbrc.2012.12.110</ext-link></td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Strain; strain background (<italic>Mus musculus</italic>)</td><td valign="top"><italic>Cdh5</italic>-WT (C57BL/6J)</td><td valign="top">DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ni.2824">10.1038/ni.2824</ext-link></td><td valign="top"/><td valign="top">Referred to as VEC-WT throughout</td></tr><tr><td valign="top">Strain; strain background (<italic>Mus musculus</italic>)</td><td valign="top"><italic>Cdh5</italic>-Y685F (C57BL/6J)</td><td valign="top">DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ni.2824">10.1038/ni.2824</ext-link></td><td valign="top"/><td valign="top">Referred to as VEC-Y685F throughout</td></tr><tr><td valign="top">Cell line (<italic>Homo-sapiens</italic>)</td><td valign="top">Human retinal microvascular endothelial</td><td valign="top">Cell Systems</td><td valign="top">Cat# ACBRI 181</td><td valign="top">Primary cells <break/>HRMEC</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-VE-cadherin pY685 (rabbit polyclonal)</td><td valign="top">DOI:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ncomms2199">10.1038/ncomms2199</ext-link></td><td valign="top"/><td valign="top">IF (1:50), <break/>WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-VE-cadherin <break/>(goat polyclonal)</td><td valign="top">R and D systems</td><td valign="top">Cat# AF1002 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2077789">AB_2077789</ext-link></td><td valign="top">IF (1:200), WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-eNOS <break/>(mouse monoclonal)</td><td valign="top">Abcam</td><td valign="top">Cat# ab76198 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1310183">AB_1310183</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Src GD11 clone <break/>(mouse monoclonal)</td><td valign="top">Merck Millipore</td><td valign="top">Cat# 05–184 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2302631">AB_2302631</ext-link></td><td valign="top">IF (1:200), WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-c-Src pY418 <break/>(rabbit polyclonal)</td><td valign="top">Invitrogen</td><td valign="top">Cat# 44–660G <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1500523">AB_1500523</ext-link></td><td valign="top">IF (1:100), WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-α-tubulin <break/>(mouse monoclonal)</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# T9026 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_477593">AB_477593</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-eNOS pS1177 <break/>(mouse monoclonal)</td><td valign="top">BD Biosciences</td><td valign="top">Cat# 612392 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_399750">AB_399750</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Akt <break/>(rabbit polyclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 9272S <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_329827">AB_329827</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Akt pS473 <break/>(rabbit monoclonal)</td><td valign="top">Cell Signaling</td><td valign="top">Cat# 4058S <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_331168">AB_331168</ext-link></td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-CD31 <break/>(rat monoclonal)</td><td valign="top">BD Biosciences</td><td valign="top">Cat# 553370 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_394816">AB_394816</ext-link></td><td valign="top">IF (1:200)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-CD68 FA-11 clone <break/>(rat monoclonal)</td><td valign="top">BIO-RAD</td><td valign="top">Cat# MCA1957 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_322219">AB_322219</ext-link></td><td valign="top">IF (1:300)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-NG2 <break/>(rabbit polyclonal)</td><td valign="top">Merck Millipore</td><td valign="top">Cat# AB5320 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_91789">AB_91789</ext-link></td><td valign="top">IF (1:300)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-ERG <break/>(rabbit monoclonal)</td><td valign="top">Abcam</td><td valign="top">Cat# Ab92513 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2630401">AB_2630401</ext-link></td><td valign="top">IF (1:200)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Donkey anti-Rabbit IgG</td><td valign="top">ThermoFisher Scientific</td><td valign="top">Cat# A-31572 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_162543">AB_162543</ext-link></td><td valign="top">IF (1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Donkey anti-Rat IgG</td><td valign="top">ThermoFisher Scientific</td><td valign="top">Cat# A-21208 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_141709">AB_141709</ext-link></td><td valign="top">IF (1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Donkey anti-Goat IgG</td><td valign="top">ThermoFisher Scientific</td><td valign="top">Cat# A-11055 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2534102">AB_2534102</ext-link></td><td valign="top">IF (1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Donkey anti-Mouse IgG, (H + L) HRP</td><td valign="top">ThermoFisher Scientific</td><td valign="top">Cat# A-16011 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2534685">AB_2534685</ext-link></td><td valign="top">WB (1:10000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Donkey anti-Rabbit IgG, (H + L) HRP</td><td valign="top">ThermoFisher Scientific</td><td valign="top">Cat# A-16023 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2534697">AB_2534697</ext-link></td><td valign="top">WB (1:10000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Donkey anti-Goat IgG, (H + L) HRP</td><td valign="top">ThermoFisher Scientific</td><td valign="top">Cat# A-15999 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2534673">AB_2534673</ext-link></td><td valign="top">WB (1:10000)</td></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">Griess assay (nitrate/nitrite colorimetric assay kit)</td><td valign="top">Cayman Chemical</td><td valign="top">Cat# 780001</td><td valign="top"/></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">CD31 microbeads, mouse</td><td valign="top">Miltenyi Biotec</td><td valign="top">Cat# 130-097-418</td><td valign="top"/></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">RNeasy Mini Kit</td><td valign="top">QIAGEN</td><td valign="top">Cat# 74104</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Nω-Methyl-L-arginine acetate salt (L-NMMA)</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# M7033</td><td valign="top"/></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">Amersham ECL Prime Western Blotting Detection</td><td valign="top">GE Healthcare</td><td valign="top">Cat# RPN2232</td><td valign="top"/></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Nos3</italic> forward</td><td valign="top">ThermoFisher Scientific</td><td valign="top">PCR primers</td><td valign="top">AAGGTGATGAGGACTCTGTGGC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Nos3</italic> reverse</td><td valign="top">ThermoFisher Scientific</td><td valign="top">PCR primers</td><td valign="top">GATATCTCGGGCAGCAGCTT</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Nos2</italic> forward</td><td valign="top">ThermoFisher Scientific</td><td valign="top">PCR primers</td><td valign="top">GGTGAAGGGACTGAGCTGTTA</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Nos2</italic> reverse</td><td valign="top">ThermoFisher Scientific</td><td valign="top">PCR primers</td><td valign="top">TGAGAACAGCACAAGGGGTTT</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Vegfa</italic> forward</td><td valign="top">ThermoFisher Scientific</td><td valign="top">PCR primers</td><td valign="top">GCACATAGAGAGAATGAGCTTCC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Vegfa</italic> reverse</td><td valign="top">ThermoFisher Scientific</td><td valign="top">PCR primers</td><td valign="top">CTCCGCTCTGAACAAGGCT</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Tbp</italic> forward</td><td valign="top">ThermoFisher Scientific</td><td valign="top">PCR primers</td><td valign="top">CCTTGTACCCTTCACCAATGAC</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Tbp</italic> reverse</td><td valign="top">ThermoFisher Scientific</td><td valign="top">PCR primers</td><td valign="top">ACAGCCAAGATTCACGGTAGA</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Ubc</italic> forward</td><td valign="top">ThermoFisher Scientific</td><td valign="top">PCR primers</td><td valign="top">CCCACACAAAGCCCCTCAAT</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Ubc</italic> reverse</td><td valign="top">ThermoFisher Scientific</td><td valign="top">PCR primers</td><td valign="top">AAGATCTGCATCGTCTCTCTCAC</td></tr><tr><td valign="top">Peptide, recombinant protein</td><td valign="top">VEGFA, recombinant, mouse</td><td valign="top">Peprotech</td><td valign="top">Cat# 450–32</td><td valign="top"/></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">Duolink In Situ PLA Probe anti-Rabbit MINUS</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# DUO92005 <break/>RID:AB_2810942</td><td valign="top"/></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">Duolink In Situ PLA Probe anti-Mouse PLUS</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# DUO92001 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2810939">AB_2810939</ext-link></td><td valign="top"/></tr><tr><td valign="top">Commercial assay, kit</td><td valign="top">Duolink In Situ Detection Reagent (Orange)</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# DUO92007</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">SuperScript III Reverse Transcriptase</td><td valign="top">Invitrogen</td><td valign="top">Cat# 18080093</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">DAF-FM diacetate (DA)</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# D1946-1MG</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">Lycopersicon Esculentum (Tomato) Lectin (LEL, TL), Fluorescein</td><td valign="top">Vector Laboratories</td><td valign="top">Cat# FL-1171–1</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">Fluoro-Max Dyed Green Aqueous Fluorescent Particles</td><td valign="top">ThermoFisher Scientific</td><td valign="top">Cat# G25</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">Hoechst 33342</td><td valign="top">ThermoFisher Scientific</td><td valign="top">Cat# H3570</td><td valign="top">IF (1:1000)</td></tr><tr><td valign="top">Other</td><td valign="top">Alexa Fluor 488-Isolectin B4</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# I21411 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2314662">AB_2314662</ext-link></td><td valign="top">IF (1:500)</td></tr><tr><td valign="top">Other</td><td valign="top">Alexa Fluor 647-Isolectin B4</td><td valign="top">Sigma-Aldrich</td><td valign="top">Cat# I32450 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_014365">SCR_014365</ext-link></td><td valign="top">IF (1:500)</td></tr><tr><td valign="top">Software</td><td valign="top">ImageJ</td><td valign="top">NIH, Bethesda, MD</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_003070">SCR_003070</ext-link></td><td valign="top"/></tr><tr><td valign="top">Software</td><td valign="top">GraphPad Prism</td><td valign="top">GraphPad</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/SCR_002798">SCR_002798</ext-link></td><td valign="top"/></tr></tbody></table></table-wrap><sec id="s2-1"><title>Animal studies</title><p><italic>Nos3<sup>S1176A/S1176A</sup></italic> mice on a C57Bl/6J background have been described (<xref ref-type="bibr" rid="bib26">Kashiwagi et al., 2013</xref>). <italic>Cdh5</italic>-WT and <italic>Cdh5-Y685F</italic> mice (referred to as VEC-WT and VEC-Y685F throughout text), also on C57Bl/6J background, were generated using a wild-type murine VE-cadherin/<italic>Cdh5</italic> cDNA construct (VEC-WT) or a mutant cDNA in which Y685 is replaced by F685 (VEC-Y685F, <xref ref-type="bibr" rid="bib54">Wessel et al., 2014</xref>). Both strains were maintained by crossing heterozygous mice. Wild-type C57BL/6J mice (Jackson Laboratory) and the Y685F strain were treated, when indicated, with Nω-methyl-<sc>l</sc>-arginine acetate salt (L-NMMA; Sigma-Aldrich) in PBS, 20 µg/g body weight, by intraperitoneal injection from postnatal (P) day 12 to P16.</p><p>Wild-type mice were also treated, when indicated, with a single dose of L-NMMA in PBS, 60 µg/g body weight, by intraperitoneal injection on P16.</p><p>Mouse husbandry and OIR-challenge took place at Uppsala University, and the Local Ethics committee approved all animal work for these studies. Animal handling was in accordance with the ARVO statement for the Use of Animals in Ophthalmologic and Vision Research. All animal experiments were repeated individually at least three times (biological repeats).</p></sec><sec id="s2-2"><title>Oxygen-induced retinopathy</title><p>A standard oxygen-induced retinopathy (OIR) model was used (<xref ref-type="bibr" rid="bib10">Connor et al., 2009</xref>). Briefly, each litter of pups was placed, along with the mother, into a chamber maintaining 75.0% oxygen (ProOx 110 sensor and AChamber, Biospherix, Parish, NY) from P7 to P12. They were then returned to normal atmosphere (~21% oxygen), until P17 (termination). The lactating mother was removed each day, P8–P11, and placed in normal atmosphere for 2 hr, to prevent oxygen toxicity. At P17, pups were weighed and sacrificed. Eyes were enucleated and fixed in 4% paraformaldehyde (PFA) at room temperature for 30 min. See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1A</xref> for data on body weights at P17 after OIR. No mice were excluded from analysis.</p></sec><sec id="s2-3"><title>Quantification of avascular area and neovascular tufts</title><p>Avascular area and neovascular tuft formation were determined by immunostaining retinas followed by imaging (Leica SP8 confocal microscope) and analysis. Quantification of total vascularized area, central avascular area, and tuft area was performed by outlining images manually in ImageJ (NIH, Bethesda, MD). Using a tilescan of IB4 staining for the entire retina, the freehand selection tool was used to demarcate the vascular front, creating a region of interest (ROI) for the total vascularized area. The freehand selection tool was used to outline IB4-positive vessels from neovascular tufts (regions with disorganized dilated vessels). The ROIs for tufts were merged into a single ROI corresponding to the total neovascular tuft area for each retina. The tuft area normalized to the total vascularized area was reported as a percentage of the total retina that contained tufts. Similarly, the avascular region was determined using the freehand selection tool to outline the central avascular regions. Regions where the superficial layer of capillaries was absent were determined and merged to form a single ROI corresponding to the entire avascular region for each retina. The avascular area normalized to the total vascularized area was reported as a percentage of the total retina that was still avascular. The researcher was blinded to the genotype of the sample when performing quantifications.</p></sec><sec id="s2-4"><title>Microsphere assay</title><p>For microsphere extravasation experiments, mice at P17 were briefly warmed under heat lamp to dilate tail veins before injection of microspheres (1% solution of 25 nm fluorescent microspheres; 50 μl per mouse into the tail vein; ThermoFisher). Microspheres circulated for 15 min. To remove blood and microspheres from the retinal vessels, mice were perfused with room temperature phosphate-buffered saline (PBS) containing Ca<sup>2+</sup>/Mg<sup>2+</sup>, using a peristaltic pump for 2 min, under full isoflurane anesthesia. The eyes were then enucleated and fixed in 4% PFA at room temperature for 30 min before dissection, IB4 staining, and mounting for microscopy (Leica SP8 confocal microscope, 63× objective).</p><p>Using ImageJ software, the microsphere channel and IB4-vessel channel (488 for Green fluorescence and 647 for IB4) were adjusted with threshold (Huang for IB4 and Triangle for FITC) for each channel. Extravasated microsphere area was calculated by measuring the signal in the green fluorescence channel after removing any signal contained within the ROI corresponding to the IB4-positive area. The Analyze Particles function was employed to quantify the microspheres. A lower limit of 10 pixels was selected to distinguish the microsphere signal from background noise. The mean area density for each group of mice was calculated from the median value of all images of the eyes of each mouse (<xref ref-type="bibr" rid="bib46">Smith et al., 2020</xref>). To quantify leakage based on microscopic images, the amount of tracer extravasation was normalized to blood vessel density. The researcher was blinded to the genotype of the sample when performing quantifications. See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1B</xref> for data on body weights at P17; microsphere analyses. No mice were excluded from analysis.</p></sec><sec id="s2-5"><title>Quantification of perfusion, pericyte coverage, and macrophage infiltration</title><p>Mice at P17 were anesthetized with an intraperitoneal injection of ketamine/xylazine (100 μg/g and 10 μg/g bodyweight). Once sedated, the mice were given a retro-orbital injection of 25 μl tomato lectin (25 mg/mL) and allowed to circulate for 5 min, followed by perfusion with room temperature PBS containing Ca<sup>2+</sup>/Mg<sup>2+</sup>, using a peristaltic pump for 2 min. The eyes were then enucleated and fixed in 1% paraformaldehyde (PFA) at room temperature for 30 min before dissection. The eyes were processed for detection of IB4, inflammatory cells (CD68+), and pericytes (NG2+) and mounted for microscopy (Leica SP8 confocal microscope, 20× objective).</p><p>Using imageJ software, macrophage infiltration was analyzed by counting the total number of CD68-positive particles in the entire retina. Pericyte coverage was analyzed by normalizing the NG2-positive area to the IB4 area of individual tufts. Perfusion was determined by normalizing the tomato lectin positive area to the IB4 area of individual tufts. The researcher was blinded to the genotype of the sample when performing quantifications. See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1C</xref> for data on body weights at P17 after OIR for inflammation, pericyte analysis, and perfusion. No mice were excluded from analysis.</p></sec><sec id="s2-6"><title>Endothelial cell isolation from mouse lung</title><p>Mouse lungs were harvested from pups (age; P8–P10), minced, and digested in 2 mg/mL collagenase type I (385 U/mg; Worthington) in PBS with Ca<sup>2+</sup>/Mg<sup>2+</sup> for 1 hr at 37°C. Cells were then isolated using CD31 Microbeads and MACS cell isolation equipment and reagents (Miltenyi Biotec). The cells were seeded at 3 × 10<sup>5</sup> cells/mL and cultured in MV2 medium with supplements and serum (PromoCell).</p></sec><sec id="s2-7"><title>Griess reagent assay</title><p>Isolated endothelial cells were seeded at 3 × 10<sup>5</sup> cells/mL into 6 cm cell culture plates and allowed to adhere at 37°C and 5% CO<sub>2</sub> overnight. After 24 hr a Griess Assay was performed (nitrate/nitrite colorimetric assay, Cayman chemical) according to the manufacturer’s instruction. Once complete, the cells were lysed in 1% (wt/vol) NP 40, 25 mM Tris–HCl pH 7.6, 0.1% SDS, 0.15 M NaCl, 1% sodium deoxycholate, and 1× Protease Inhibitor Cocktail (Roche), and concentration of nitrate/nitrite was normalized against protein concentration, measured using the BCA protein detection kit (ThermoFisher).</p></sec><sec id="s2-8"><title>Proximity ligation assay</title><p>Isolated endothelial cells, serum starved at 37°C in MV2 medium (containing no growth factors) 3 hr before stimulation with murine VEGFA<sub>164</sub> (50 ng/mL; R and D Systems), followed by fixation in 3% PFA for 3 min, permeabilized in 0.1% Triton X-100 for 3 min, and postfixed in 3% PFA for 15 min. Samples were blocked in Duolink blocking buffer for 2 hr at 37°C and used for proximity ligation assay (PLA). The Duolink protocol (Sigma-Aldrich) was followed using anti-phospho-Src Tyr 418 (Invitrogen) and total c-Src (Merck Millipore) antibodies, and oligonucleotide-linked secondary antibodies, denoted PLUS and MINUS probes, followed by the detection of reactions with fluorescent probes. Upon completion of the PLA protocol, cells were counterstained with antibodies against VE-cadherin (R and D systems), and Hoechst 33342 (ThermoFisher) to detect nuclei. Only cells positive for VE-cadherin were imaged and analyzed. To determine c-Src p418 association with VE-cadherin, a mask of the VE-cadherin channel was created and only points that aligned completely within the VE-cadherin mask were counted and expressed against the area of VE-cadherin per field of view (ImageJ software, NIH). As a technical control for each experiment, the same procedure was performed with the omission of either of the primary antibodies or the PLUS/MINUS probes.</p></sec><sec id="s2-9"><title>Immunofluorescent staining</title><p>Whole mount immunostaining was performed on PFA-fixed retinas incubated in blocking buffer for 2 hr (Buffer b; bovine serum albumin [BSA]/2% fetal calf serum [FCS]/0.05% Na-deoxycholate/0.5% Triton X-100/0.02% Na Azide in PBS). Incubation with primary antibodies over night at 4°C on a rocking platform was followed by incubation with secondary antibodies overnight at 4°C. Retinas were mounted on slides using Fluormount G. Images were taken by Leica SP8 confocal microscope and acquired with the 10× or 63× objective. Processing and quantification of images was done with ImageJ software (NIH). Quantification in the retina of total vascularized area, central avascular area, and area covered by neovascular tufts was performed by outlining images manually in ImageJ. Avascular area and tuft area were normalized to the total vascularized area of the retina.</p></sec><sec id="s2-10"><title>Quantitative real-time PCR</title><p>RNA from retinas were purified using RNeasy Kit (Qiagen). One microgram of RNA was reverse transcribed using SuperScript III (Invitrogen), and quantitative PCR were assayed using <italic>Mus musculus</italic> primers against <italic>Vegfa</italic> (Mm00437306_m1, ThermoFisher), <italic>Nos3</italic> (Mm00435217_m1), and <italic>Nos2</italic> (Mm00440502_m1). The expression levels were normalized against TATA binding protein (TBP) <italic>Mus musculus</italic> (Mm01277042_m1, ThermoFisher) and Ubiqutin C (<italic>UBC</italic>) <italic>Mus musculus</italic> (Mm02525934_g1, ThermoFisher).</p></sec><sec id="s2-11"><title>Cell culture and treatment</title><p>Human retinal microvascular endothelial cells (HRMECs; Cell Systems, #ACBRI 181) were cultured in a complete classic medium kit with serum and CultureBoost (Cell Systems, #4Z0–500). The cells were supplied mycoplasma free. HRMECs were used and passaged in 10 cm cell culture plates coated with attachment factor, between passages 5–10 for all experiments. All cells were serum starved for 3 hr at 37°C in MV2 medium (containing no growth factors) before stimulation. Murine VEGFA (Peprotech) was used at 50 ng/mL for in vitro analyses. L-NMMA (1 mM in PBS) was administrated 1 hr before stimulation with VEGFA.</p></sec><sec id="s2-12"><title>Immunoblot</title><p>Cells were lysed in 1% (wt/vol) NP 40, 25 mM Tris–HCl pH 7.6, 0.1% SDS, 0.15 M NaCl, 1% sodium deoxycholate, 1× Protease Inhibitor Cocktail (Roche), 1 mM Na<sub>3</sub>VO<sub>4</sub> (Sigma), and centrifuged at 21,100 g for 10 min. Protein concentration was measured with the BCA protein detection kit (ThermoFisher). Proteins were separated on a 4–12% Bis–Tris polyacrylamide gel (Novex by Life Technologies) and transferred to an Immobilon-P PVDF membrane (Millipore) using the Criterion Blotter System (Bio–Rad). The membrane was blocked with 3–5% skim milk in Tris-buffered saline (TBS; 0.1% Tween). For phosphotyrosine antibodies, blocking was done in 5% BSA in TBS, 0.1% Tween. The membrane was incubated with first antibodies overnight at 4°C. Membranes were then washed in TBS, 0.1% Tween and incubated with horseradish peroxidase (HRP)-conjugated secondary anti-mouse antibody (1:10,000; Invitrogen) in 3–5% skim milk, respectively, followed by final wash in TBS, 0.1% Tween and development using ECL prime (GE Healthcare). Luminescence signal was detected by the ChemiDoc MP system (Bio–Rad) and densitometry performed using Image Lab software (ver 4, Bio-Rad).</p></sec><sec id="s2-13"><title>Antibodies</title><p>The retinal vasculature was stained with directly conjugated Alexa Fluor 488-Isolectin B4 (1:200; Sigma, I21411) or Alexa Fluor 647-Isolectin B4 (1:200; Sigma, I32450). EC junctions and phosphorylated VE-cadherin were detected with anti-VE-cadherin antibody (1:200, R and D, AF1002) and affinity purified rabbit antibodies against VE-cadherin pY685; a kind gift from Prof. Elisabetta Dejana, Uppsala University/IFOM Milano (<xref ref-type="bibr" rid="bib34">Orsenigo et al., 2012</xref>). For PLAs, VE-cadherin was detected using goat anti-VE-cadherin antibody (1:200, R and D Systems, AF1002). c-Src was detected using rabbit anti-Src (GD11 clone) antibody (1:200, Merck Millipore, Mouse, 05–184). Phosphorylated c-Src was assessed using rabbit anti-Src pY418 antibody (1:100, Invitrogen, 44–660G). Nuclei were detected using Hoechst 33342 (1:1000, ThermoFisher, H3570). For immunoblotting, the following antibodies were used as primaries: mouse-anti-α−tubulin (1:1000, Sigma, T9026), mouse anti-eNOS (1:1000, Abcam, ab76198), mouse anti-eNOS pS1177 (1:1000, BD, 612392), rabbit anti-Akt (1:1000, Cell Signaling, 9272S), rabbit anti-Akt pS473 (1:1000, Cell Signaling, 4058S), rabbit anti-Src (GD11 clone) antibody (1:1000, Merck Millipore, Mouse, 05–184), rabbit anti-Src pY418 antibody (1:1000, Invitrogen, 44–660G), goat anti-VE-cadherin (1:1000, R and D, AF1002), and rabbit anti-VE-cadherin pY685 (1:1000, DOI:10.1038/ncomms2199). Detection: Amersham ECL prime Western blotting detection reagent (GE Healthcare, RPN2232).</p></sec><sec id="s2-14"><title>DAF-FM DA assay</title><p>Intracellular NO was measured in real time using the NO-specific fluorescence probe DAF-FM DA solution (Sigma-Aldrich). DAF-FM DA diffuses freely across the membrane and is hydrolyzed by intracellular esterases, resulting in the formation of DAF-FM. Intracellular DAF-FM reacts with the NO oxidation product N<sub>2</sub>O<sub>2</sub>, which generates the stable highly fluorescent derivative DAF-FM triazole. Cells were washed with modified HEPES buffer (20 mM HEPES buffer [Gibco] with 5 mM glucose, 50 µM <sc>l</sc>-arginine, and 0.1% BSA, pH 7.0–7.4), incubated with 5 µM DAF-FM DA in modified HEPES buffer for 30 min at room temperature, washed again, and finally incubated in modified HEPES buffer for 30 min at 37°C in the absence or presence of 1 mM L-NMMA. Fluorescence (emission wavelength, 485 nm; excitation wavelength, 538 nm) was measured at 37°C from 1 to 10 min using a fluorescence microtiter plate reader (Synergy HTX Multi-Mode Reader, BioTek). eNOS activity was expressed as the VEGFA-dependent increase in fluorescence per microgram of cellular protein. To determine the cellular protein content, the same cells were lysed in 1% (vol/vol) Triton X-100 and analyzed for protein content with the BCA protein detection kit. DAF-FM DA experiments were repeated three times. Within each experiment, four wells were used for each NO measurement.</p></sec><sec id="s2-15"><title>Statistical analysis</title><p>Statistical analysis was performed using GraphPad Prism 6 (GraphPad). An unpaired Student’s t-test was used to compare means among two experimental groups. Two-way ANOVAs were performed when two factors were involved, for example, treatment and genotype. Multiple comparisons post hoc tests were chosen based on how many group comparisons were made. In all analyses, p&lt;0.05 was considered a statistically significant result. Values shown are the mean, with standard error of the mean (S.E.M.) used as the dispersion measure. Biological replicates refer to individual mice/samples in a single experiment. Separate/individual experiments refer to experiments done at different times/days with independently generated material. A statistical method of sample size calculation was not used during the study design.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Reduced neoangiogenic tuft formation in C57BL/6 OIR with suppressed NO formation</title><p>To determine whether eNOS inhibition affects pathological angiogenesis in retinopathy in C57BL/6J mice, pups were exposed to 75% oxygen from P7 to P12 (hyperoxic period) where after they were placed at normal, atmospheric conditions (21% oxygen; relative hypoxic period) from P12 to P17 (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). During the P7–P12 hyperoxic period, VEGFA expression is suppressed, leading to endothelial cell death and avascularity in the superficial vessel layer (reviewed in <xref ref-type="bibr" rid="bib41">Scott and Fruttiger, 2010</xref>). The relative decrease in oxygen concentration upon return to normal atmosphere at P12–P17 induces hypoxia-inducible factor-dependent gene regulation, causing oxygen-induced retinopathy (OIR) and the formation of neoangiogenic tufts (<xref ref-type="bibr" rid="bib45">Smith et al., 1994</xref>) (see <xref ref-type="fig" rid="fig1">Figure 1B</xref> for schematic outline).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Suppressed tuft formation in the <italic>Nos3<sup>S1176A/S1176A</sup></italic> retina after OIR-challenge.</title><p>(<bold>A</bold>) Outline of OIR-challenge protocol; pups were placed in 75% O<sub>2</sub> (hyperoxia) between P7 and P12, followed by return to normal atmosphere (relative hypoxia) until P17. (<bold>B</bold>) Schematic representation of vascular abnormalities after OIR in P17 retinas. (<bold>C</bold>) Nitric oxide formation determined using a Griess assay, expressed as the combined concentration of nitrite and nitrate, the end products of NO, reacting with molecules in biological fluids. Mean ± S.E.M. n = 3 mice/genotype. ****p&lt;0.0001; t-test. (<bold>D</bold>) Representative images of whole mount retinas from <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> mice, collected at P17 after OIR-challenge, stained with isolectin B4 (IB4). Avascular area is marked in magenta and tufts in blue. Scale bar = 500 µm. (<bold>E, F</bold>) Tuft area (<bold>E</bold>) and avascular area (<bold>F</bold>) expressed as percentage of total vascular area at P17. (<bold>G, H</bold>) Tuft size in µm2 (<bold>G</bold>) and total number/FOV in P17 mice (<bold>H</bold>). For (<bold>E</bold>–<bold>H</bold>): mean ± S.E.M. n = 7 (<italic>Nos3<sup>+/+</sup></italic>) and 5 (<italic>Nos3<sup>S1176A/S1176A</sup></italic>) mice. *p&lt;0.05; t-test.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Excel file containing numerical values collected from NO formation assays and OIR-induced tuft formation experiments in Nos3<sup>+/+</sup> and Nos3<sup>S1176A/S1176A</sup> mice shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplements 1</xref>–<xref ref-type="fig" rid="fig1s4">4</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64944-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64944-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Postnatal development of <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinal vasculature.</title><p>(<bold>A</bold>) Representative images of <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas collected at P7, stained with isolectin B4 (IB4). (<bold>B, C</bold>) Quantification of vascular area (<bold>B</bold>) and outgrowth from the optic nerve (<bold>C</bold>) at P7 in <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> pups. (<bold>D</bold>) Representative images of the vessel front from whole mount retinas collected at P7 stained with Isolectin-B4 (IB4, red, upper), ERG (yellow, upper), and CD34 (green, lower), to visualize vessel outgrowth and tip cells in <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinal vasculature. Scale bar = 50 µm. (<bold>E–G</bold>) Filopodia length (<bold>E</bold>), tip cell number (<bold>F</bold>), branch points (<bold>G</bold>) in <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas at P7. Mean ± S.E.M. n = 3 (<italic>Nos3<sup>+/+</sup></italic>) and 4 (<italic>Nos3<sup>S1176A/S1176A</sup></italic>) mice, five to six images per mouse; t-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64944-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Retina characteristics in <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> P12 pups.</title><p>(<bold>A</bold>) Representative images of whole mount <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas collected at P12 after the vessel destruction phase of OIR and before vessel regrowth, stained with isolectin B4 (IB4). Scale bar = 500 µm. (<bold>B</bold>) Avascular area in <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas at P12 after OIR. n = 4 (<italic>Nos3<sup>+/+</sup></italic>) and 5 (<italic>Nos3<sup>S1176A/S1176A</sup></italic>) mice, three independent experiments; t-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64944-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Pericytes, macrophage influx, and vascular perfusion in OIR-challenged <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas.</title><p>(<bold>A</bold>) Representative images of tufts visualized by IB4 binding and co-stained for NG2 (red) to mark pericytes in <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas collected at P17. Scale bar = 100 μm. (<bold>B</bold>) Pericyte coverage expressed as the NG2-positive area normalized to the IB4 area. Mean ± S.E.M. n = 4 (<italic>Nos3<sup>+/+</sup></italic>) and 4 (Nos3<sup>S1176A/S1176A</sup>) mice. t-test. (<bold>C</bold>) Representative images of one leaf of the retina (IB4) co-stained for CD68 (yellow) to mark circulatory/tissue macrophages in <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas collected at P17. Scale bar = 200 μm. (<bold>D</bold>) The number of CD68-positive macrophages in the entire retina represented by particle number, normalized to the retina area. Mean ± S.E.M. n = 4 (<italic>Nos3<sup>+/+</sup></italic>) and 4 (<italic>Nos3<sup>S1176A/S1176A</sup></italic>) mice. t-test. (<bold>E</bold>) Representative images of tufts with circulating tomato lectin (green), co-stained with IB4 in <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas collected at P17. Scale bar = 100 μm. (<bold>F</bold>) Tuft perfusion, expressed as the area of tomato lectin normalized to the IB4 area. Mean ± S.E.M. n = 4 (<italic>Nos3<sup>+/+</sup></italic>) and 4 (<italic>Nos3<sup>S1176A/S1176A</sup></italic>) mice. *p&lt;0.05; t-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64944-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Expression of Nos2, Nos3, and Vegfa in <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas.</title><p>(<bold>A–C</bold>) qPCR of <italic>Nos3</italic> (<bold>A</bold>), Nos2 (<bold>B</bold>), and <italic>Vegfa</italic> (<bold>C</bold>) expression in P17 normoxic and OIR-challenged <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> mouse retinas. (<bold>D, E</bold>) Relative levels of <italic>Nos2</italic> and <italic>Nos3</italic> compared against standard curves of <italic>TBP</italic> and <italic>UBC</italic> in <italic>Nos3<sup>+/+</sup></italic> (<bold>D</bold>) and <italic>Nos3<sup>S1176A/S1176A</sup></italic> (<bold>E</bold>) retinas. Mean ± S.E.M. n = 5 (<italic>Nos3<sup>+/+</sup></italic>) and 5 (<italic>Nos3<sup>S1176A/S1176A</sup></italic>) mice. Three independent experiments. *, **, ***p&lt;0.05, 0.01, 0.001; two-way ANOVA, Sidak’s multiple comparison test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64944-fig1-figsupp4-v2.tif"/></fig></fig-group><p>To specifically address the role of eNOS in vascular retinal disease, we used a genetic model in which eNOS S1176 (mouse numbering, <xref ref-type="bibr" rid="bib20">Fulton et al., 1999</xref>; S1177 in human) is replaced by alanine (A) (<xref ref-type="bibr" rid="bib26">Kashiwagi et al., 2013</xref>). Phosphorylation of eNOS on this serine residue is a prerequisite for eNOS-driven NO production, which was verified using a Griess assay on isolated endothelial cells from <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> mice (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Mice were subjected to the OIR regimen (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). After OIR-challenge, <italic>Nos3<sup>S1176A/S1176A</sup></italic> P17 retinas showed reduced pathological tuft area compared to <italic>Nos3<sup>+/+</sup></italic> (<xref ref-type="fig" rid="fig1">Figure 1E</xref>), while the extent of avascularity was the same (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). The average size of individual tufts was reduced in the <italic>Nos3<sup>S1176A/S1176A</sup></italic> pups (<xref ref-type="fig" rid="fig1">Figure 1G</xref>), while the total number of tufts formed after OIR was unaffected (<xref ref-type="fig" rid="fig1">Figure 1H</xref>).</p><p>The suppressed formation of neoangiogenic tufts in the absence of eNOS S1176 phosphorylation was not due to developmental defects as <italic>Nos3<sup>S1176A/S1176A</sup></italic> mice showed normal postnatal vascular development. Vascular plexus area and outgrowth in the retina, tip cell number and appearance, as well as branch points were all similar between the wild-type and the <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–G</xref>). At P12 after OIR-challenge, there was also no difference in the degree of avascularity in the retina between <italic>Nos3<sup>S1176A/S1176A</sup></italic> and <italic>Nos3<sup>+/+</sup></italic> pups, indicating that the strains responded similarly to the hyperoxic challenge (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A,B</xref>). Moreover, no differences were found when comparing <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas with regard to coverage of vessels by NG2-positive pericytes (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A,B</xref>) or the presence of CD68-positive macrophages (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3C,D</xref>), at P17. However, vessel perfusion was enhanced in <italic>Nos3<sup>S1176A/S1176A</sup></italic> tufts compared to the wild type (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3E,F</xref>), most likely due to the smaller tufts formed in the <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas.</p><p>Importantly, the reduced tuft area in the <italic>Nos3<sup>S1176A/S1176A</sup></italic> condition was not a result of differences in <italic>Nos3</italic> or <italic>Nos2</italic> expression between the <italic>Nos3</italic><sup>+/+</sup> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> mice before or after the OIR-challenge (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4A,B</xref>). Reduced tuft area was also not a result of reduced VEGFA production as an equally induced level of VEGFA was seen in the mutant and wild-type retinas (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4C</xref>). It should also be noted that the low relative expression level of <italic>Nos2</italic> (encoding inducible nitric oxide synthase [iNOS]) compared to <italic>Nos3</italic> (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4D,E</xref>) emphasizes the primary role of eNOS as a source of endothelial NO, both in the unchallenged and OIR-treated condition.</p></sec><sec id="s3-2"><title>VEGFA induces eNOS phosphorylation and activity</title><p>VEGFA produced during the relative hypoxia phase (P12–P17) is an important instigator of edema in retinopathy (<xref ref-type="bibr" rid="bib10">Connor et al., 2009</xref>; <xref ref-type="bibr" rid="bib16">Dor et al., 2001</xref>). VEGFA/VEGFR2 signaling and vessel leakage correlates with phosphorylation of VE-cadherin on Y685 (<xref ref-type="bibr" rid="bib29">Li et al., 2016</xref>; <xref ref-type="bibr" rid="bib46">Smith et al., 2020</xref>; <xref ref-type="bibr" rid="bib54">Wessel et al., 2014</xref>). The level of pY685 VE-cadherin was examined by immunostaining of <italic>Nos3<sup>+/</sup></italic><sup>+</sup> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas at P17 after OIR-challenge. pY685 VE-cadherin immunostaining, normalized to the total VE-cadherin area, was significantly lower in <italic>Nos3<sup>S1176A/S1176A</sup></italic> tufts than in the WT tufts (<xref ref-type="fig" rid="fig2">Figure 2A,B</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Suppressed c-Src Y418 and VE-cadherin Y685 phosphorylation in <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas and isolated endothelial cells.</title><p>(<bold>A</bold>) Representative maximum intensity projections of similar sized tufts from <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas showing VE-cadherin (green), pY685 VE-cadherin (red), and isolectin B4 (IB4; cyan). Scale bar = 50 μm. (<bold>B</bold>) Ratio of pY685 positive area/total VE-cadherin positive area. Mean ± S.E.M n = 3–6 images per group from 5 (<italic>Nos3<sup>+/+</sup>)</italic> and 5 (<italic>Nos3<sup>S1176A/S1176A</sup></italic>) mice, three independent experiments, *p&lt;0.05; t-test. (<bold>C</bold>) Representative images of VE-cadherin staining (green) and proximity ligation assay (PLA) to detect c-Src pY418 (magenta) in isolated mouse lung endothelial cells (iEC) from <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> mice. Scale bar = 20 µM. (<bold>D</bold>) c-Src pY418 PLA dots detected in PBS and VEGFA (50 ng/mL)-treated iECs from <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> mouse lungs. Data expressed as the number of dots per field of view. (<bold>E</bold>) c-Src pY418 PLA dots co-localized with VE-cadherin (green), normalized against total VE-cadherin area in the field of view. Mean ± S.E.M. Cells isolated from n = 4 (<italic>Nos3<sup>+/+</sup>)</italic> and 4 (<italic>Nos3<sup>S1176A/S1176A</sup></italic>) mice, from three separate experiments. *, **p&lt;0.05, 0.01; two-way ANOVA, Sidak’s multiple comparisons test.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Excel file containing numerical values collected from biochemical analyses shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplements 1</xref>–<xref ref-type="fig" rid="fig2s3">3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64944-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64944-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>VEGFA induced eNOS phosphorylation and activity in vitro.</title><p>(<bold>A</bold>) Effect of VEGFA (V; 50 ng/mL; 1, 5, 10 min), histamine (H; 10 µM, 1, 5, 10 min), or medium (C, control) on eNOS phosphorylation at S1177 in cultured Human Retinal Microvascular Endothelial Cells (HRMEC). (<bold>B</bold>) Quantification of eNOS pS1177/total eNOS normalized to tubulin. Mean ± S.E.M. n = 3 independent experiments. *p&lt;0.05; two-way ANOVA, Sidak’s multiple comparison test. (<bold>C</bold>) Antibody validation by immunoblotting for eNOS on HRMECs transfected with a control siRNA or Nos3-specific siRNA followed by treatment with VEGFA (50 ng/mL; 5 min). (<bold>D</bold>) Antibody validation by immunoblotting for eNOS pS1177 on HRMECs transfected with a control siRNA or Nos3-specific siRNA followed by treatment with VEGFA (50 ng/mL; 5 min). (<bold>E</bold>) Quantification of NO production in HRMECs treated with PBS or VEGFA (50 ng/mL, for 1, 5, or 10 min) using the cell-permeable fluorescent probe DAF-FM DA. (<bold>F</bold>) Quantification of NO production in HRMECs pre-treated with PBS or L-NMMA (1 mM) before VEGFA stimulation (50 ng/mL, 5 min). Mean ± S.E.M. n = 12, three independent experiments. *, **, ****p&lt;0.05, 0.01, 0.0001; two-way ANOVA, Sidak’s multiple comparison test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64944-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>VEGFA induced phosphorylation of eNOS, AKT, VE-cadherin, and c-Src in vitro.</title><p>(<bold>A</bold>) Representative immunoblots and the effect of VEGFA (50 ng/mL; 1, 5, 10, 30 min) on eNOS, eNOS pS1177, AKT, AKT pS473, VE-cadherin, VE-cadherin pY685, c-Src, SFK pY418, and tubulin in cultured Human Retinal Microvascular Endothelial Cells (HRMEC) treated with a PBS vehicle or 1 mM L-NMMA for 1 hr. (<bold>B</bold>) Quantification of eNOS pS1177/total eNOS (normalized to tubulin). (<bold>C</bold>) Quantification of AKT pS473/total AKT (normalized to tubulin). (<bold>D</bold>) Quantification of VE-cadherin pY685/total VE-cadherin (normalized to tubulin). (<bold>E</bold>) Quantification of SFK pY418/total c-Src (normalized to tubulin) Mean ± S.E.M. n = 3 independent experiments. *, ***p&lt;0.05, 0.001 (indicates significance between vehicle and L-NMMA-treated samples, stimulated with VEGFA as indicated). Two-way ANOVA, Sidak’s multiple comparison test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64944-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>c-Src pY418 immunostaining and PLA controls.</title><p>(<bold>A</bold>) Representative maximum intensity projections of tufts from <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas immunostained for VE-cadherin (green), c-Src pY418 (red), and IB4 (cyan). (<bold>B</bold>) Quantification of pY418-positive area/total VE-cadherin area. n = 3 images per group from 3 (<italic>Nos3<sup>+/+</sup></italic>) and 4 (<italic>Nos3<sup>S1176A/S1176A</sup></italic>) mice from two separate experiments; t-test. (<bold>C</bold>) Representative images of VE-cadherin staining (green) and negative controls for proximity ligation in isolated mouse lung endothelial cells (iEC) from <italic>Nos3<sup>+/+</sup></italic> mice. Controls were performed by incubation with only one of the necessary antibodies or, one of the PLUS or MINUS PLA probes (mouse and rabbit secondary antibodies), which should inhibit rolling circle DNA synthesis. This allows for the detection of non-specific ligation or uncontrolled rolling circle DNA synthesis. Scale bar = 20 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64944-fig2-figsupp3-v2.tif"/></fig></fig-group><p>We explored the potency of VEGFA/VEGFR2 in inducing NO generation and how this related to phosphorylation of VE-cadherin. eNOS was phosphorylated on S1177 in VEGFA-treated human retinal microvascular endothelial cells (HRMEC). Induction of eNOS phosphorylation appeared with similar kinetics but slightly more potently by VEGFA than by the inflammatory mediator histamine (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A,B</xref>; see <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C,D</xref> for antibody validation), a well-known inducer of eNOS activity (<xref ref-type="bibr" rid="bib51">Thors et al., 2004</xref>). eNOS phosphorylation was accompanied by NO production in response to VEGFA stimulation, as assessed using the fluorescent probe, DAF-FM DA added to the HRMEC culture medium. NO accumulated significantly by 1 min stimulation and still persisted at 10 min (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>). DAF-FM DA fluorescence, and therefore NO production, was blocked by incubating cells with L-NMMA (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>), to the level of the untreated control. Combined, these data show that VEGFA is a potent inducer of eNOS activity and NO production.</p></sec><sec id="s3-3"><title>VE-cadherin phosphorylation at Y685 is reduced in <italic>Nos3<sup>S1176A/S1176A</sup></italic> vessels after OIR due to the inhibition of c-Src Y418 phosphorylation</title><p>Phosphorylation of VE-cadherin on Y685 correlates with activation of the cytoplasmic tyrosine kinase c-Src (<xref ref-type="bibr" rid="bib34">Orsenigo et al., 2012</xref>; <xref ref-type="bibr" rid="bib53">Wallez et al., 2007</xref>). The NO-generating reagent, SNAP, can increase the levels of activated c-Src phosphorylated on Y418 in fibroblast cultures (<xref ref-type="bibr" rid="bib37">Rahman et al., 2010</xref>), indicating a potential role for NO in c-Src activation. We therefore tested whether eNOS 1176 phosphorylation correlates with phosphorylation of c-Src at Y418. In vitro, the cell-permeable NOS inhibitor L-NMMA had no effect on VEGFA-induced phosphorylation of eNOS (S1177). There was also no significant effect of L-NMMA treatment on VEGFA-induced phosphorylation of AKT (S473) (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A–C</xref>); VEGFA-mediated AKT activation is a prerequisite for phosphorylation of eNOS at S1177 (<xref ref-type="bibr" rid="bib9">Chen and Meyrick, 2004</xref>; <xref ref-type="bibr" rid="bib40">Schleicher et al., 2009</xref>). In contrast, phosphorylation of VE-cadherin at Y685 was attenuated and delayed (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D</xref>), an indication of reduced permeability (<xref ref-type="bibr" rid="bib46">Smith et al., 2020</xref>). Immunoblotting for SFK Y418 phosphorylation, representing c-Src activation, showed a biphasic induction in the control. Treatment with L-NMMA efficiently suppressed the second pY418 peak at 10 min of VEGFA stimulation (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2E</xref>). The inhibition by L-NMMA of the second Y418 peak observed here mirrors results obtained by Li et al., where a leakage-resistant VEGFR2 Y949F mutant also lacked the second pY418 peak in immunoblots (<xref ref-type="bibr" rid="bib29">Li et al., 2016</xref>). Upon in vivo analyses, immunostaining for c-Src pY418 however failed to reveal differences in pY418 c-Src levels between <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3 <sup>S1176A/S1176A</sup></italic> retinas (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A,B</xref>). These results indicate that the pY418 antibody is not specific to c-Src phosphorylation and likely recognizes several related Src family kinases (SFKs) such as Yes and Fyn. Thus, the double pY418 peaks appearing in the immunoblots may be due to phosphorylation of distinct SFKs.</p><p>To overcome the potential lack in antibody specificity for c-Src, we next employed the PLA (<xref ref-type="bibr" rid="bib47">Söderberg et al., 2006</xref>). For this purpose, we used oligonucleotide-ligated secondary antibodies detecting primary antibodies against murine c-Src protein and the conserved (across c-Src, Yes, and Fyn) pY418 residue on endothelial cells isolated from lungs of <italic>Nos<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> mice and treated or not with VEGFA. The PLA was combined with counterstaining for VE-cadherin (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). As shown in <xref ref-type="fig" rid="fig2">Figure 2D</xref>, VEGFA stimulation increased PLA spots, representing pY418 specifically on c-Src, at least fivefold in the isolated endothelial cells (iECs) from <italic>Nos<sup>+/+</sup></italic> mice, but not in iECs from <italic>Nos3<sup>S1176A/S1176A</sup></italic> mice (see <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3C</xref> for PLA negative controls). The c-Src pY418 PLA spots co-localized with VE-cadherin immunostaining (<xref ref-type="fig" rid="fig2">Figure 2E</xref>).</p><p>These data indicate that eNOS S1176 phosphorylation and the consequent formation of NO are essential for the accumulation of active c-Src at endothelial junctions to induce the phosphorylation of VE-cadherin at Y685.</p></sec><sec id="s3-4"><title>Suppressed vascular leakage in <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas after OIR-challenge</title><p>In the retina, the blood–retina barrier (BRB) controls vascular permeability; however, the BRB is disrupted in retinopathies, causing edema and vision loss (<xref ref-type="bibr" rid="bib27">Klaassen et al., 2013</xref>; <xref ref-type="bibr" rid="bib56">Zhao et al., 2015</xref>). Edema correlates with increased vessel permeability, which is dependent on the phosphorylation status of VE-cadherin (<xref ref-type="bibr" rid="bib54">Wessel et al., 2014</xref>) and c-Src activity (<xref ref-type="bibr" rid="bib53">Wallez et al., 2007</xref>). To assess the role for eNOS specifically in vessel leakage after hypoxia-driven VEGFA production, 25 nm fluorescent microspheres were injected in the tail vein of P17 <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> mice, after OIR-challenge. Confocal image analysis showed accumulation of microspheres outside the vascular tufts, in agreement with enhanced vessel leakage upon OIR (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The accumulation of microspheres normalized to tuft area was significantly lower in <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas compared to <italic>Nos3</italic><sup>+/+</sup> (<xref ref-type="fig" rid="fig3">Figure 3B</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Suppressed microsphere leakage in <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas.</title><p>(<bold>A</bold>) Representative images of similar sized tufts from <italic>Nos3<sup>+/+</sup></italic> and <italic>Nos3<sup>S1176A/S1176A</sup></italic> mice showing isolectin B4 (IB4; red), and leakage of tail-vein injected FITC-conjugated 25 nm microspheres (cyan) around the tufts. Scale bar = 100 µM. Lower panels show leakage maps. Dots that do not overlap with vessels (beige) are considered extravascular. (<bold>B</bold>) Quantification of the average area of extravascular microspheres normalized to IB4 area. Mean ± S.E.M. n = 4 (<italic>Nos3<sup>+/+</sup></italic>) and 4 (<italic>Nos3<sup>S1176A/S1176A</sup></italic>) mice, 6–15 images per mouse. *p&lt;0.05, t-test.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Excel file containing numerical values collected from microsphere leakage experiments from OIR retinas in Nos3<sup>+/+</sup> and Nos3<sup>S1176A/S1176A</sup> mice shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64944-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64944-fig3-v2.tif"/></fig></sec><sec id="s3-5"><title>Reduced tuft area as a result of pharmacological inhibition of NO formation</title><p>The <italic>Nos3<sup>S1176A/S1176A</sup></italic> mouse is unable to produce NO in the endothelium due to the non-phosphorylatable alanine replacing S1176. As we could not unequivocally exclude that the vascular effects observed in the <italic>Nos3<sup>S1176A/S1176A</sup></italic> mutant were dependent on non-NO synthesis events linked to S1176 phosphorylation, we used L-NMMA to inhibit the formation of NO.</p><p>Intraperitoneal injections of L-NMMA (20 µg/g body weight) were given daily to wild-type C57Bl/6J pups during P12–P17 (injections on days P12–P16), thus treatment was initiated before pathological neovessels were established (prevention therapy). This preventive administration had no effect on NG2-positive pericyte coverage or infiltration of CD68-positive macrophages (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–D</xref>). However, L-NMMA treatment significantly reduced the area of vascular tufts formed by P17 (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref>) but did not affect the avascular area (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). The average tuft size was decreased (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), while the total number of individual tufts increased with L-NMMA treatment (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). As smaller tufts can fuse to form larger structures (<xref ref-type="bibr" rid="bib36">Prahst et al., 2020</xref>), the increase in individual tufts in the L-NMMA-treated litter mates may reflect the suppressed growth and fusion of the tufts. The constitutive inhibition of eNOS activation in the <italic>Nos3<sup>S1176A/S1176A</sup></italic> retina resulted in tufts that were more efficiently perfused than in the wild-type retina (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3E,F</xref>). In contrast, with L-NMMA treatment, tuft perfusion was equivalent to that in the vehicle-treated pups (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E,F</xref>). It is expected that constitutive genetic inhibition and pharmacological inhibition during an interval after the hyperoxia treatment would differently suppress tuft formation and growth and result in distinct tuft morphologies, with more or less open lumens.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>OIR-challenged mice treated with NO inhibitor L-NMMA.</title><p>(<bold>A</bold>) Representative images of whole mount retinas from PBS- and L-NMMA-treated (P12–P16) wild-type C57Bl/6 mice, collected on P17 after OIR-challenge, and stained with isolectin B4 (IB4). Avascular area as a result of OIR is marked in magenta and tufts in blue. Scale bar = 500 µm. (<bold>B, C</bold>) Tuft area and avascular area expressed as percentage of total vascular area at P17. (<bold>D, E</bold>) Tuft size in µm<sup>2</sup> and total number of tufts/field of vision at P17. Mean ± S.E.M. n = 8 (PBS) and 9 (L-NMMA) treated mice. *, **p&lt;0.05, 0.01; t-test. (<bold>F</bold>) Representative images of whole mount IB4-stained P17 retinas from OIR-challenged VEC-WT and VEC-Y685F mice injected with PBS or L-NMMA during P12-P16. Avascular area is marked in magenta and tufts in blue. Scale bar = 500 µm. (<bold>G</bold>) Tuft area normalized to total vascular area in PBS or L-NMMA-treated VEC-WT and VEC-Y685F retinas. (<bold>H</bold>) Avascular area normalized to total vascular area. Mean ± S.E.M. n = 8 (VEC-WT) and 8 (VEC-Y685F) mice. **, ***p&lt;0.01, 0.001; two-way ANOVA, Sidak’s multiple comparison test.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Excel file containing numerical values collected from OIR-induced tuft formation experiments in PBS- and L-NMMA-treated WT retinas shown in <xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64944-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64944-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Pericytes, macrophage influx, and vascular perfusion in OIR-challenged WT retinas treated with PBS or L-NMMA.</title><p>(<bold>A</bold>) Representative images of tufts visualized by IB4 binding and co-stained for NG2 (red) to mark pericytes in PBS and L-NMMA-treated retinas collected at P17. Scale bar = 100 μm. (<bold>B</bold>) Pericyte coverage expressed as the NG2-positive area normalized to the IB4 area. Mean ± S.E.M. n = 4 (PBS) and 4 (L-NMMA) mice. t-test. (<bold>C</bold>) Representative images of one leaf of the retina (IB4) co-stained for CD68 (yellow) to mark circulatory/tissue macrophages in PBS and L-NMMA treated retinas collected at P17. Scale bar = 200 μm. (<bold>D</bold>) The number of CD68-positive macrophages in the entire retina represented by particle number, normalized to the retina area. Mean ± S.E.M. n = 4 (Nos3<sup>+/+</sup>) and 4 (Nos3<sup>S1176A/S1176A</sup>) mice. t-test. (<bold>E</bold>) Representative images tufts with circulating tomato lectin (green) co-stained with IB4 in PBS- and L-NMMA-treated retinas collected at P17. Scale bar = 100 μm. (<bold>F</bold>) Tuft perfusion, expressed as the tomato lectin area normalized to the IB4 area Mean ± S.E.M. n = 4 (PBS) and 4 (L-NMMA) mice. t-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64944-fig4-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s3-6"><title>NO and VE-cadherin Y685 phosphorylation operate on the same pathway regulating vascular leakage</title><p>To further explore the relationship between NO and VE-cadherin pY685 in the formation of leaky, pathological vessels, we used mice expressing wild-type VE-cadherin (VEC-WT) or mutant VE-cadherin wherein phosphorylation at position 685 is abolished by exchanging the tyrosine (Y) for phenylalanine (F), VEC-Y685F (<xref ref-type="bibr" rid="bib54">Wessel et al., 2014</xref>). VEC-Y685F mice show suppressed induction of vascular leakage in the healthy skin (<xref ref-type="bibr" rid="bib54">Wessel et al., 2014</xref>). We hypothesized that if NO modulates vascular leakage and tuft formation via a non-VE-cadherin Y685 pathway, L-NMMA would impart an additional reduction in tuft area to OIR-challenged VEC-Y685F mice. To test whether the VEC-Y685F mouse would respond to NOS inhibition, L-NMMA (20 µg/g body weight) was administered by intraperitoneal injection of VEC-WT and VEC-685F mice during the relative hypoxic period (injections on days P12–P16). Results show that L-NMMA treatment did not further suppress tuft formation in Y685F mice at P17. The reduction in tuft area was similar, about 50%, in PBS and L-NMMA-treated Y685F retinas and comparable to that seen in L-NMMA-treated VEC-WT mice (<xref ref-type="fig" rid="fig4">Figure 4F,G</xref>). The avascular area remained unaffected by all treatments (<xref ref-type="fig" rid="fig4">Figure 4H</xref>).</p></sec><sec id="s3-7"><title>Single-dose L-NMMA decreases vascular leakage in the retina</title><p>We next aimed to more closely mimic a clinical situation by administering L-NMMA to OIR-challenged wild-type mice with established pathological vessels (intervention therapy). Mice were given one injection of L-NMMA (60 µg/g body weight) at P16. At P17, microspheres were injected and after 15 min, the experiment was terminated. The area of extravascular microspheres, assessed after normalization to tuft area (<xref ref-type="fig" rid="fig5">Figure 5A,B</xref>) or to total microsphere area (<xref ref-type="fig" rid="fig5">Figure 5A,C</xref>), was reduced by 50–60% after the single-dose treatment with L-NMMA compared to PBS. Of note, the total microsphere area was not affected by the L-NMMA treatment (<xref ref-type="fig" rid="fig5">Figure 5D</xref>), indicating that microspheres to a large extent were present in the vascular lumen in the L-NMMA-treated condition, while in the PBS control, they had crossed the disrupted barrier to the extravascular space. The tuft area was not affected by the L-NMMA treatment (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Analyses of a parallel cohort of mice showed that there was no effect of the single-dose L-NMMA treatment on vessel pericyte coverage, macrophage infiltration, or tuft perfusion (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A–F</xref>). Thus, these data indicate that leakage could be suppressed even from established neovascular structures.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Decreased leakage from retinal vascular tufts after single-dose L-NMMA treatment.</title><p>(<bold>A</bold>) Representative images of tufts from <italic>Nos3<sup>+/+</sup></italic> (wild type) mice treated with PBS or L-NMMA (60 µg/g body weight) 24 hr before tail-vein injection of 25 nm microspheres. Retinas were stained using isolectin B4 (IB4; cyan), microspheres (red) appear in and around the tufts. Scale bar = 100 µM. Lower panels show leakage maps. Dots that do not overlap with vessels (beige) are considered extravascular. (<bold>B</bold>) Quantification of the average area of extravascular microspheres normalized to IB4 area. (<bold>C</bold>) Quantification of the average area of extravascular microspheres normalized to total microsphere area. (<bold>D</bold>) Quantification of average total microsphere area in PBS- or L-NMMA-treated wild-type mouse retinas. (<bold>E</bold>) Quantification of tuft area normalized to total vascular area. Mean ± S.E.M. n = 5 (PBS) and 5 (L-NMMA) treated mice. *p&lt;0.05; t-test.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Excel file containing numerical values collected from microsphere leakage analyses from OIR retinas in single-treated PBS and L-NMMA WT mice shown in <xref ref-type="fig" rid="fig5">Figure 5</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64944-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64944-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Pericytes, macrophage influx, and vascular perfusion in OIR-challenged WT retinas treated with a single injection of PBS or L-NMMA.</title><p>(<bold>A</bold>) Representative images of tufts visualized by IB4 binding and co-stained for NG2 (red) to mark pericytes in single-dose-treated PBS and L-NMMA retinas collected at P17. Scale bar = 100 μm. (<bold>B</bold>) Pericyte coverage expressed as the NG2-positive area normalized to the IB4 area. Mean ± S.E.M. n = 4 (PBS) and 4 (L-NMMA) mice. t-test. (<bold>C</bold>) Representative images of one leaf of the retina (IB4) co-stained for CD68 (yellow) to mark circulatory/tissue macrophages in single-dose-treated PBS and L-NMMA retinas collected at P17. Scale bar = 200 μm. (<bold>D</bold>) The number of CD68-positive macrophages in the entire retina represented by particle number, normalized to the retina area. Mean ± S.E.M. n = 4 (<italic>Nos3<sup>+/+</sup></italic>) and 4 (<italic>Nos3<sup>S1176A/S1176A</sup></italic>) mice. t-test. (<bold>E</bold>) Representative images tufts with circulating tomato lectin (green) co-stained with IB4 in single-dose-treated PBS and L-NMMA retinas collected at P17. Scale bar = 100 μm. (<bold>F</bold>) Tuft perfusion, expressed as the area of tomato lectin normalized to the IB4 area. Mean ± S.E.M. n = 4 (PBS) and 4 (L-NMMA) mice. t-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64944-fig5-figsupp1-v2.tif"/></fig></fig-group></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>The results presented here show that eNOS/NO plays a role in the postcapillary venous system by directly affecting the endothelial barrier to exacerbate vascular hyperpermeability in retinopathy (<xref ref-type="fig" rid="fig6">Figure 6</xref>). According to the consensus model, eNOS-generated NO regulates vascular permeability by inducing the relaxation of perivascular smooth muscle cells. NO produced in endothelial cells diffuses across the vascular wall and activates soluble guanylate cyclase leading to protein kinase G activation in vSMC, lowering cellular Ca<sup>2+</sup>, and promoting vascular relaxation, increased blood flow, and reduced blood pressure (<xref ref-type="bibr" rid="bib48">Surks et al., 1999</xref>). Indeed, vessel dilation is a part of the tissue deterioration seen in diabetic retinopathy (<xref ref-type="bibr" rid="bib5">Bek, 2013</xref>; <xref ref-type="bibr" rid="bib22">Grimm and Willmann, 2012</xref>). However, there is also evidence for a direct role for eNOS and NO in endothelial cells, as constitutive eNOS deficiency inhibits inflammatory hyperpermeability in the mouse cremaster muscle treated with platelet-activating factor (<xref ref-type="bibr" rid="bib23">Hatakeyama et al., 2006</xref>). Moreover, NO can regulate phosphorylation of VE-cadherin in adheren junctions in vitro in microvascular endothelial cell cultures (<xref ref-type="bibr" rid="bib14">Di Lorenzo et al., 2013</xref>). It is likely that these multifaceted effects of eNOS/NO are differently established in different vessel types. eNOS/NO-dependent vessel dilation is dependent on the vSMC coverage in arterioles and arteries; in contrast, adherens junction stability affects mainly the postcapillary venular bed (<xref ref-type="bibr" rid="bib34">Orsenigo et al., 2012</xref>). In the skin, prevenular capillaries and postcapillary venules, with sparse vSMC coverage, respond to VEGFA with increased paracellular permeability, while arterioles/arteries do not (<xref ref-type="bibr" rid="bib25">Honkura et al., 2018</xref>). These distinctions are important as exaggerated and chronic VEGFA-driven paracellular permeability in disease leads to edema and eventually to tissue destruction (<xref ref-type="bibr" rid="bib31">Nagy et al., 2012</xref>). Therefore, we explored the consequences of NO deficiency using a mutant eNOS mouse model, with a serine to alanine exchange at 1176, as well as treatment with the NO inhibitor L-NMMA, to examine how attenuating NO production affects VEGFA-dependent pathological angiogenesis in ocular disease.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>eNOS/NO modulates VE-cadherin Y685 phosphorylation via c-Src in a VEGFA/VEGFR2-dependent manner.</title><p>VEGFA through VEGFR2 and its phosphosite Y1212 induces a chain of consecutive reactions in endothelial cells: phosphorylation of AKT at S473 and eNOS at S1176. The VEGFR2 phosphosite Y949 mediates phosphorylation of c-Src at Y418 and of VE-cadherin at Y685. Combined, these activating phosphorylation reactions disrupt the vascular barrier by dissociating VE-cadherin’s homophilic interactions, resulting in macromolecular leakage. eNOS/NO regulates activation of c-Src to enhance VE-cadherin Y685 phosphorylation and internalization.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-64944-fig6-v2.tif"/></fig><p>Our data shows that while the attenuation of eNOS S1176 phosphorylation was dispensable for vascular development in the retina and for endothelial survival during hyperoxia, growth of pathological vessel tufts in the subsequent phase of relative hypoxia was suppressed, while pericyte coverage and inflammation remained unaffected. Also, treatment with L-NMMA during the hypoxic phase reduced growth of vascular tufts in the retina. In agreement with earlier literature, we conclude that eNOS activity and NO formation influence pathological angiogenesis in the eye (<xref ref-type="bibr" rid="bib2">Ando et al., 2002</xref>; <xref ref-type="bibr" rid="bib6">Brooks et al., 2001</xref>; <xref ref-type="bibr" rid="bib17">Edgar et al., 2012</xref>). Of note, tufts that were established in the <italic>Nos3<sup>S1176A/S1176A</sup></italic> mice leaked less, in spite of similar levels of VEGFA being produced as in the wild-type retina. In an attempt to mimic the clinical situation, we treated P16 mice with established vascular tufts with a single dose of L-NMMA. At the examination 24 hr later, tuft area remained unaffected, while the leakage of 25 nm microspheres was reduced by 50–60%. Whether leakage regulation is separable from the regulation of growth of new vessels has been a matter of debate. Pathological angiogenesis in the retina is intimately associated with leakage and edema (<xref ref-type="bibr" rid="bib46">Smith et al., 2020</xref>). Exactly how junction stability plays a role in the neoangiogenic process is unclear. However, leakage and the production of a provisional matrix is postulated to be a prerequisite for the growth of angiogenic sprouts (reviewed in <xref ref-type="bibr" rid="bib31">Nagy et al., 2012</xref>). With the effects of the L-NMMA intervention treatment shown here, we can conclude that these responses indeed can be separated, at least in the short term.</p><p>L-NMMA and its analog, L-NAME, induce vasoconstriction by halting the NO/soluble guanylyl cyclase signaling pathway and consequent vasodilation (reviewed in <xref ref-type="bibr" rid="bib1">Ahmad et al., 2018</xref>; <xref ref-type="bibr" rid="bib50">Thoonen et al., 2013</xref>). Thus, a daily intake of L-NAME in rats (40–75 μg/g/day for 4–8 weeks) leads to vasoconstriction (<xref ref-type="bibr" rid="bib38">Ribeiro et al., 1992</xref>; <xref ref-type="bibr" rid="bib44">Simko et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">Vrankova et al., 2019</xref>; <xref ref-type="bibr" rid="bib55">Zanfolin et al., 2006</xref>). NOS inhibitors have also been used clinically, for example, by administration of L-NMMA to increase the mean arterial pressure in cardiogenic shock. In a typical regimen, 1 mg.kg<sup>−1</sup>.hr<sup>−1</sup> of L-NMMA is administered over 5 hr (<xref ref-type="bibr" rid="bib11">Cotter et al., 2000</xref>). While we cannot exclude an effect on vasoconstriction with the single IP injection of L-NMMA used here (60 μg/g), blood flow appeared unaffected as equal amounts of microspheres arrived in the retinal vasculature, while leakage into the extravascular space was substantially reduced in the L-NMMA treated mice compared to the controls. The leakage suppression did not involve changes in pericyte coverage of vessels or in the degree of inflammation. While perfusion was enhanced in tufts that still formed in the <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas after OIR-challenge, there was no effect on perfusion in tufts remaining after multiple- or single-dose L-NMMA treatment, possibly reflecting differences in tuft morphology and the degree of vessel patency.</p><p>Mechanistically, our results place c-Src downstream of eNOS activity. c-Src has also been placed upstream of eNOS by c-Src’s regulation of the PI3K-AKT pathway, of importance for eNOS activation (<xref ref-type="bibr" rid="bib24">Haynes et al., 2003</xref>). VEGFR2-induced activation of c-Src has however been mapped to the pY949 residue in VEGFR2 (<xref ref-type="bibr" rid="bib29">Li et al., 2016</xref>), while activation of Akt is dependent on Y1212 (<xref ref-type="bibr" rid="bib49">Testini et al., 2019</xref>). In VEGFA-stimulated endothelial cells, c-Src is implicated in phosphorylation of VE-cadherin at Y685 and potentially other tyrosine residues, to induce vascular permeability (<xref ref-type="bibr" rid="bib34">Orsenigo et al., 2012</xref>; <xref ref-type="bibr" rid="bib53">Wallez et al., 2007</xref>). The fact that the mutant VEC-Y685F mice in which the Y685 residue has been replaced with a non-phosphorylatable phenylalanine were resistant to L-NMMA inhibition, indicates that the VEGFR2 Y1212/eNOS/NO pathway acts on adherens junction through c-Src (<xref ref-type="bibr" rid="bib29">Li et al., 2016</xref>). Combined, our data support a model in which eNOS phosphorylation at S1176 is required for the activation of c-Src, which in turn phosphorylates VE-cadherin at Y685, inducing transient disintegration of adherens junctions and increased paracellular permeability (<xref ref-type="fig" rid="fig6">Figure 6</xref>). These in vivo results potentially provide meaningful mechanistic and therapeutic insights with regard to retinopathy of prematurity (<xref ref-type="bibr" rid="bib12">Cunha-Vaz et al., 2011</xref>).</p><p>A considerable challenge in the analysis of c-Src activity is the close structural relatedness between the kinase domains of c-Src and the related SFKs Yes and Fyn (<xref ref-type="bibr" rid="bib39">Sato et al., 2009</xref>), which are also expressed in endothelial cells. The amino acid sequence covering the activating tyrosine is entirely conserved between these three cytoplasmic tyrosine kinases such that the antibodies against pY418 c-Src in fact reacts with all three SFKs. In agreement, immunoblotting using antibodies against pY418 c-Src resulted in biphasic peaks of activity possibly reflecting activation of different SFKs. Moreover, pY418 immunostaining of wild-type and <italic>Nos3<sup>S1176A/S1176A</sup></italic> retinas after OIR failed to reveal a dependence on eNOS catalytic activity for activation of c-Src, in agreement with the findings of <xref ref-type="bibr" rid="bib14">Di Lorenzo et al., 2013</xref>. However, combining oligonucleotide-linked secondary antibodies reacting with c-Src protein and pY418 Src in a PLA on isolated endothelial cells demonstrated a critical role for eNOS activity on accumulation of active, pY418-positive c-Src at endothelial junctions. The question remains how eNOS/NO influences c-Src activity? NO can couple with cysteine thiols to form S-nitroso-thiols, which may affect the folding and function of the target protein. In accordance, Rahman et al. demonstrated S-nitrosylation of c-Src at the kinase domain cysteine 498, correlating with increased c-Src activity (<xref ref-type="bibr" rid="bib37">Rahman et al., 2010</xref>).</p><p>Although not experimentally addressed in this study, retinal diseases, such as diabetic retinopathy and adult macular degeneration, are accompanied by excessive permeability (<xref ref-type="bibr" rid="bib3">Antonetti et al., 2012</xref>; <xref ref-type="bibr" rid="bib7">Campochiaro, 2015</xref>). Of note, patients with diabetic retinopathy have elevated levels of NO in the aqueous humor, and particular eNOS polymorphisms are associated with protection or increased risk for diabetic retinopathy (for a review, see <xref ref-type="bibr" rid="bib33">Opatrilova et al., 2018</xref>) and macular edema (<xref ref-type="bibr" rid="bib4">Awata et al., 2004</xref>). Our results show that pharmacological inhibition of NO production after OIR challenge in mice can prevent vascular leakage. Thus, NO inhibitors applied in combination with anti-VEGF therapy, delivered in low but still efficient doses, could possibly be of clinical benefit. Local delivery of NOS inhibitors may be needed to avoid drawbacks with systemic delivery, such as hypertension, or any other vasoconstriction-associated adverse events. A limitation of the findings reported here was that neither the multiple-dose nor single-dose L-NMMA treatment improved perfusion of remaining tufts after OIR challenge. However, as tuft formation and leakage were suppressed with the multiple-dose treatment, a relative larger fraction of vessels remained healthy, with normal perfusion.</p><p>In conclusion, the data presented here establish a critical role for eNOS in endothelial cells, regulating c-Src activation downstream of VEGFA/VEGFR2, and thereby, in VE-cadherin-regulated endothelial junction stability and vascular leakage in retinal pathology.</p></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We gratefully acknowledge the expert assistance of Pernilla Martinsson, Uppsala University.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Validation, Investigation, Visualization, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Supervision, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Resources, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Mouse husbandry and oxygen-induced retinopathy (OIR) challenge took place at Uppsala University, and the University board of animal experimentation approved all animal work for the studies (ethical permit 5.2.18-8927/16). Animal handling was in accordance to the ARVO statement for the Use of Animals in Ophthalmologic and Vision Research. Professional animal care was provided and overseen by University veterinarians. Every effort was made to minimize suffering of the animal.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Body weights for OIR experiments.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-64944-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-64944-transrepform-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 1–5. Source data files have also been deposited with Dryad: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.x69p8czhv">https://doi.org/10.5061/dryad.x69p8czhv</ext-link>.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Love</surname><given-names>D</given-names></name><name><surname>Ninchoji</surname><given-names>T</given-names></name><name><surname>Claesson-Welsh</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>eNOS/NO and their role in modifying the vascular barrier in retinopathy - Source data</data-title><source>Dryad Digital Repository</source><pub-id assigning-authority="Dryad" pub-id-type="doi">10.5061/dryad.x69p8czhv</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname> <given-names>A</given-names></name><name><surname>Dempsey</surname> <given-names>S</given-names></name><name><surname>Daneva</surname> <given-names>Z</given-names></name><name><surname>Azam</surname> <given-names>M</given-names></name><name><surname>Li</surname> <given-names>N</given-names></name><name><surname>Li</surname> <given-names>P-L</given-names></name><name><surname>Ritter</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Role of nitric oxide in the cardiovascular and renal systems</article-title><source>International Journal of Molecular Sciences</source><volume>19</volume><elocation-id>2605</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19092605</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ando</surname> <given-names>A</given-names></name><name><surname>Yang</surname> <given-names>A</given-names></name><name><surname>Mori</surname> <given-names>K</given-names></name><name><surname>Yamada</surname> <given-names>H</given-names></name><name><surname>Yamada</surname> <given-names>E</given-names></name><name><surname>Takahashi</surname> <given-names>K</given-names></name><name><surname>Saikia</surname> <given-names>J</given-names></name><name><surname>Kim</surname> <given-names>M</given-names></name><name><surname>Melia</surname> <given-names>M</given-names></name><name><surname>Fishman</surname> <given-names>M</given-names></name><name><surname>Huang</surname> <given-names>P</given-names></name><name><surname>Campochiaro</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Nitric oxide is proangiogenic in the retina and choroid</article-title><source>Journal of Cellular Physiology</source><volume>191</volume><fpage>116</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1002/jcp.10083</pub-id><pub-id pub-id-type="pmid">11920687</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonetti</surname> <given-names>DA</given-names></name><name><surname>Klein</surname> <given-names>R</given-names></name><name><surname>Gardner</surname> <given-names>TW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Diabetic retinopathy</article-title><source>New England Journal of Medicine</source><volume>366</volume><fpage>1227</fpage><lpage>1239</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1005073</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awata</surname> <given-names>T</given-names></name><name><surname>Neda</surname> <given-names>T</given-names></name><name><surname>Iizuka</surname> <given-names>H</given-names></name><name><surname>Kurihara</surname> <given-names>S</given-names></name><name><surname>Ohkubo</surname> <given-names>T</given-names></name><name><surname>Takata</surname> <given-names>N</given-names></name><name><surname>Osaki</surname> <given-names>M</given-names></name><name><surname>Watanabe</surname> <given-names>M</given-names></name><name><surname>Nakashima</surname> <given-names>Y</given-names></name><name><surname>Sawa</surname> <given-names>T</given-names></name><name><surname>Inukai</surname> <given-names>K</given-names></name><name><surname>Inoue</surname> <given-names>I</given-names></name><name><surname>Shibuya</surname> <given-names>M</given-names></name><name><surname>Mori</surname> <given-names>K</given-names></name><name><surname>Yoneya</surname> <given-names>S</given-names></name><name><surname>Katayama</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Endothelial nitric oxide synthase gene is associated with diabetic macular edema in type 2 diabetes</article-title><source>Diabetes Care</source><volume>27</volume><fpage>2184</fpage><lpage>2190</lpage><pub-id pub-id-type="doi">10.2337/diacare.27.9.2184</pub-id><pub-id pub-id-type="pmid">15333482</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bek</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Regional morphology and pathophysiology of retinal vascular disease</article-title><source>Progress in Retinal and Eye Research</source><volume>36</volume><fpage>247</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.preteyeres.2013.07.002</pub-id><pub-id pub-id-type="pmid">23892140</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname> <given-names>SE</given-names></name><name><surname>Gu</surname> <given-names>X</given-names></name><name><surname>Samuel</surname> <given-names>S</given-names></name><name><surname>Marcus</surname> <given-names>DM</given-names></name><name><surname>Bartoli</surname> <given-names>M</given-names></name><name><surname>Huang</surname> <given-names>PL</given-names></name><name><surname>Caldwell</surname> <given-names>RB</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>42</volume><fpage>222</fpage><lpage>228</lpage><pub-id pub-id-type="pmid">11133872</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campochiaro</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Molecular pathogenesis of retinal and choroidal vascular diseases</article-title><source>Progress in Retinal and Eye Research</source><volume>49</volume><fpage>67</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.preteyeres.2015.06.002</pub-id><pub-id pub-id-type="pmid">26113211</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network Investigators</collab><name><surname>Morin</surname> <given-names>J</given-names></name><name><surname>Luu</surname> <given-names>TM</given-names></name><name><surname>Superstein</surname> <given-names>R</given-names></name><name><surname>Ospina</surname> <given-names>LH</given-names></name><name><surname>Lefebvre</surname> <given-names>F</given-names></name><name><surname>Simard</surname> <given-names>MN</given-names></name><name><surname>Shah</surname> <given-names>V</given-names></name><name><surname>Shah</surname> <given-names>PS</given-names></name><name><surname>Kelly</surname> <given-names>EN</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Neurodevelopmental outcomes following Bevacizumab injections for retinopathy of prematurity</article-title><source>Pediatrics</source><volume>137</volume><elocation-id>e20153218</elocation-id><pub-id pub-id-type="doi">10.1542/peds.2015-3218</pub-id><pub-id pub-id-type="pmid">27244705</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>JX</given-names></name><name><surname>Meyrick</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Hypoxia increases Hsp90 binding to eNOS via PI3K-Akt in porcine coronary artery endothelium</article-title><source>Laboratory Investigation</source><volume>84</volume><fpage>182</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1038/labinvest.3700027</pub-id><pub-id pub-id-type="pmid">14661033</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connor</surname> <given-names>KM</given-names></name><name><surname>Krah</surname> <given-names>NM</given-names></name><name><surname>Dennison</surname> <given-names>RJ</given-names></name><name><surname>Aderman</surname> <given-names>CM</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Guerin</surname> <given-names>KI</given-names></name><name><surname>Sapieha</surname> <given-names>P</given-names></name><name><surname>Stahl</surname> <given-names>A</given-names></name><name><surname>Willett</surname> <given-names>KL</given-names></name><name><surname>Smith</surname> <given-names>LE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis</article-title><source>Nature Protocols</source><volume>4</volume><fpage>1565</fpage><lpage>1573</lpage><pub-id pub-id-type="doi">10.1038/nprot.2009.187</pub-id><pub-id pub-id-type="pmid">19816419</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cotter</surname> <given-names>G</given-names></name><name><surname>Kaluski</surname> <given-names>E</given-names></name><name><surname>Blatt</surname> <given-names>A</given-names></name><name><surname>Milovanov</surname> <given-names>O</given-names></name><name><surname>Moshkovitz</surname> <given-names>Y</given-names></name><name><surname>Zaidenstein</surname> <given-names>R</given-names></name><name><surname>Salah</surname> <given-names>A</given-names></name><name><surname>Alon</surname> <given-names>D</given-names></name><name><surname>Michovitz</surname> <given-names>Y</given-names></name><name><surname>Metzger</surname> <given-names>M</given-names></name><name><surname>Vered</surname> <given-names>Z</given-names></name><name><surname>Golik</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock</article-title><source>Circulation</source><volume>101</volume><fpage>1358</fpage><lpage>1361</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.101.12.1358</pub-id><pub-id pub-id-type="pmid">10736276</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunha-Vaz</surname> <given-names>J</given-names></name><name><surname>Bernardes</surname> <given-names>R</given-names></name><name><surname>Lobo</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Blood-Retinal barrier</article-title><source>European Journal of Ophthalmology</source><volume>21</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.5301/EJO.2010.6049</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daruich</surname> <given-names>A</given-names></name><name><surname>Matet</surname> <given-names>A</given-names></name><name><surname>Moulin</surname> <given-names>A</given-names></name><name><surname>Kowalczuk</surname> <given-names>L</given-names></name><name><surname>Nicolas</surname> <given-names>M</given-names></name><name><surname>Sellam</surname> <given-names>A</given-names></name><name><surname>Rothschild</surname> <given-names>PR</given-names></name><name><surname>Omri</surname> <given-names>S</given-names></name><name><surname>Gélizé</surname> <given-names>E</given-names></name><name><surname>Jonet</surname> <given-names>L</given-names></name><name><surname>Delaunay</surname> <given-names>K</given-names></name><name><surname>De Kozak</surname> <given-names>Y</given-names></name><name><surname>Berdugo</surname> <given-names>M</given-names></name><name><surname>Zhao</surname> <given-names>M</given-names></name><name><surname>Crisanti</surname> <given-names>P</given-names></name><name><surname>Behar-Cohen</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mechanisms of macular edema: beyond the surface</article-title><source>Progress in Retinal and Eye Research</source><volume>63</volume><fpage>20</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.preteyeres.2017.10.006</pub-id><pub-id pub-id-type="pmid">29126927</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Lorenzo</surname> <given-names>A</given-names></name><name><surname>Lin</surname> <given-names>MI</given-names></name><name><surname>Murata</surname> <given-names>T</given-names></name><name><surname>Landskroner-Eiger</surname> <given-names>S</given-names></name><name><surname>Schleicher</surname> <given-names>M</given-names></name><name><surname>Kothiya</surname> <given-names>M</given-names></name><name><surname>Iwakiri</surname> <given-names>Y</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Huang</surname> <given-names>PL</given-names></name><name><surname>Sessa</surname> <given-names>WC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>eNOS-derived nitric oxide regulates endothelial barrier function through VE-cadherin and rho GTPases</article-title><source>Journal of Cell Science</source><volume>126</volume><fpage>5541</fpage><lpage>5552</lpage><pub-id pub-id-type="doi">10.1242/jcs.115972</pub-id><pub-id pub-id-type="pmid">24046447</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Diabetic Retinopathy Clinical Research Network</collab><name><surname>Wells</surname> <given-names>JA</given-names></name><name><surname>Glassman</surname> <given-names>AR</given-names></name><name><surname>Ayala</surname> <given-names>AR</given-names></name><name><surname>Jampol</surname> <given-names>LM</given-names></name><name><surname>Aiello</surname> <given-names>LP</given-names></name><name><surname>Antoszyk</surname> <given-names>AN</given-names></name><name><surname>Arnold-Bush</surname> <given-names>B</given-names></name><name><surname>Baker</surname> <given-names>CW</given-names></name><name><surname>Bressler</surname> <given-names>NM</given-names></name><name><surname>Browning</surname> <given-names>DJ</given-names></name><name><surname>Elman</surname> <given-names>MJ</given-names></name><name><surname>Ferris</surname> <given-names>FL</given-names></name><name><surname>Friedman</surname> <given-names>SM</given-names></name><name><surname>Melia</surname> <given-names>M</given-names></name><name><surname>Pieramici</surname> <given-names>DJ</given-names></name><name><surname>Sun</surname> <given-names>JK</given-names></name><name><surname>Beck</surname> <given-names>RW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Aflibercept, Bevacizumab, or ranibizumab for diabetic macular edema</article-title><source>The New England Journal of Medicine</source><volume>372</volume><fpage>1193</fpage><lpage>1203</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1414264</pub-id><pub-id pub-id-type="pmid">25692915</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dor</surname> <given-names>Y</given-names></name><name><surname>Porat</surname> <given-names>R</given-names></name><name><surname>Keshet</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis</article-title><source>American Journal of Physiology-Cell Physiology</source><volume>280</volume><fpage>C1367</fpage><lpage>C1374</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.2001.280.6.C1367</pub-id><pub-id pub-id-type="pmid">11350731</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edgar</surname> <given-names>K</given-names></name><name><surname>Gardiner</surname> <given-names>TA</given-names></name><name><surname>van Haperen</surname> <given-names>R</given-names></name><name><surname>de Crom</surname> <given-names>R</given-names></name><name><surname>McDonald</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>eNOS overexpression exacerbates vascular closure in the obliterative phase of OIR and increases angiogenic drive in the subsequent proliferative stage</article-title><source>Investigative Opthalmology &amp; Visual Science</source><volume>53</volume><fpage>6833</fpage><lpage>6850</lpage><pub-id pub-id-type="doi">10.1167/iovs.12-9797</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fruttiger</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Development of the retinal vasculature</article-title><source>Angiogenesis</source><volume>10</volume><fpage>77</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1007/s10456-007-9065-1</pub-id><pub-id pub-id-type="pmid">17322966</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukumura</surname> <given-names>D</given-names></name><name><surname>Gohongi</surname> <given-names>T</given-names></name><name><surname>Kadambi</surname> <given-names>A</given-names></name><name><surname>Izumi</surname> <given-names>Y</given-names></name><name><surname>Ang</surname> <given-names>J</given-names></name><name><surname>Yun</surname> <given-names>CO</given-names></name><name><surname>Buerk</surname> <given-names>DG</given-names></name><name><surname>Huang</surname> <given-names>PL</given-names></name><name><surname>Jain</surname> <given-names>RK</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability</article-title><source>PNAS</source><volume>98</volume><fpage>2604</fpage><lpage>2609</lpage><pub-id pub-id-type="doi">10.1073/pnas.041359198</pub-id><pub-id pub-id-type="pmid">11226286</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulton</surname> <given-names>D</given-names></name><name><surname>Gratton</surname> <given-names>JP</given-names></name><name><surname>McCabe</surname> <given-names>TJ</given-names></name><name><surname>Fontana</surname> <given-names>J</given-names></name><name><surname>Fujio</surname> <given-names>Y</given-names></name><name><surname>Walsh</surname> <given-names>K</given-names></name><name><surname>Franke</surname> <given-names>TF</given-names></name><name><surname>Papapetropoulos</surname> <given-names>A</given-names></name><name><surname>Sessa</surname> <given-names>WC</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Regulation of endothelium-derived nitric oxide production by the protein kinase akt</article-title><source>Nature</source><volume>399</volume><fpage>597</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1038/21218</pub-id><pub-id pub-id-type="pmid">10376602</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannotta</surname> <given-names>M</given-names></name><name><surname>Trani</surname> <given-names>M</given-names></name><name><surname>Dejana</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>VE-Cadherin and endothelial adherens junctions: active guardians of vascular integrity</article-title><source>Developmental Cell</source><volume>26</volume><fpage>441</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2013.08.020</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimm</surname> <given-names>C</given-names></name><name><surname>Willmann</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Hypoxia in the eye: a two-sided coin</article-title><source>High Altitude Medicine &amp; Biology</source><volume>13</volume><fpage>169</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1089/ham.2012.1031</pub-id><pub-id pub-id-type="pmid">22994516</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatakeyama</surname> <given-names>T</given-names></name><name><surname>Pappas</surname> <given-names>PJ</given-names></name><name><surname>Hobson</surname> <given-names>RW</given-names></name><name><surname>Boric</surname> <given-names>MP</given-names></name><name><surname>Sessa</surname> <given-names>WC</given-names></name><name><surname>Durán</surname> <given-names>WN</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Endothelial nitric oxide synthase regulates microvascular hyperpermeability <italic>in vivo</italic></article-title><source>The Journal of Physiology</source><volume>574</volume><fpage>275</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2006.108175</pub-id><pub-id pub-id-type="pmid">16675496</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haynes</surname> <given-names>MP</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Sinha</surname> <given-names>D</given-names></name><name><surname>Russell</surname> <given-names>KS</given-names></name><name><surname>Hisamoto</surname> <given-names>K</given-names></name><name><surname>Baron</surname> <given-names>R</given-names></name><name><surname>Collinge</surname> <given-names>M</given-names></name><name><surname>Sessa</surname> <given-names>WC</given-names></name><name><surname>Bender</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Src kinase mediates phosphatidylinositol 3-Kinase/Akt-dependent rapid endothelial Nitric-oxide synthase activation by estrogen</article-title><source>Journal of Biological Chemistry</source><volume>278</volume><fpage>2118</fpage><lpage>2123</lpage><pub-id pub-id-type="doi">10.1074/jbc.M210828200</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honkura</surname> <given-names>N</given-names></name><name><surname>Richards</surname> <given-names>M</given-names></name><name><surname>Laviña</surname> <given-names>B</given-names></name><name><surname>Sáinz-Jaspeado</surname> <given-names>M</given-names></name><name><surname>Betsholtz</surname> <given-names>C</given-names></name><name><surname>Claesson-Welsh</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Intravital imaging-based analysis tools for vessel identification and assessment of concurrent dynamic vascular events</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>2746</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-04929-8</pub-id><pub-id pub-id-type="pmid">30013228</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kashiwagi</surname> <given-names>S</given-names></name><name><surname>Atochin</surname> <given-names>DN</given-names></name><name><surname>Li</surname> <given-names>Q</given-names></name><name><surname>Schleicher</surname> <given-names>M</given-names></name><name><surname>Pong</surname> <given-names>T</given-names></name><name><surname>Sessa</surname> <given-names>WC</given-names></name><name><surname>Huang</surname> <given-names>PL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>eNOS phosphorylation on serine 1176 affects insulin sensitivity and adiposity</article-title><source>Biochemical and Biophysical Research Communications</source><volume>431</volume><fpage>284</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2012.12.110</pub-id><pub-id pub-id-type="pmid">23291238</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klaassen</surname> <given-names>I</given-names></name><name><surname>Van Noorden</surname> <given-names>CJ</given-names></name><name><surname>Schlingemann</surname> <given-names>RO</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions</article-title><source>Progress in Retinal and Eye Research</source><volume>34</volume><fpage>19</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.preteyeres.2013.02.001</pub-id><pub-id pub-id-type="pmid">23416119</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krock</surname> <given-names>BL</given-names></name><name><surname>Skuli</surname> <given-names>N</given-names></name><name><surname>Simon</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hypoxia-induced angiogenesis: good and evil</article-title><source>Genes &amp; Cancer</source><volume>2</volume><fpage>1117</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1177/1947601911423654</pub-id><pub-id pub-id-type="pmid">22866203</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Padhan</surname> <given-names>N</given-names></name><name><surname>Sjöström</surname> <given-names>EO</given-names></name><name><surname>Roche</surname> <given-names>FP</given-names></name><name><surname>Testini</surname> <given-names>C</given-names></name><name><surname>Honkura</surname> <given-names>N</given-names></name><name><surname>Sáinz-Jaspeado</surname> <given-names>M</given-names></name><name><surname>Gordon</surname> <given-names>E</given-names></name><name><surname>Bentley</surname> <given-names>K</given-names></name><name><surname>Philippides</surname> <given-names>A</given-names></name><name><surname>Tolmachev</surname> <given-names>V</given-names></name><name><surname>Dejana</surname> <given-names>E</given-names></name><name><surname>Stan</surname> <given-names>RV</given-names></name><name><surname>Vestweber</surname> <given-names>D</given-names></name><name><surname>Ballmer-Hofer</surname> <given-names>K</given-names></name><name><surname>Betsholtz</surname> <given-names>C</given-names></name><name><surname>Pietras</surname> <given-names>K</given-names></name><name><surname>Jansson</surname> <given-names>L</given-names></name><name><surname>Claesson-Welsh</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>11017</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms11017</pub-id><pub-id pub-id-type="pmid">27005951</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mintz-Hittner</surname> <given-names>HA</given-names></name><name><surname>Kennedy</surname> <given-names>KA</given-names></name><name><surname>Chuang</surname> <given-names>AZ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity</article-title><source>New England Journal of Medicine</source><volume>364</volume><fpage>603</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1007374</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname> <given-names>JA</given-names></name><name><surname>Dvorak</surname> <given-names>AM</given-names></name><name><surname>Dvorak</surname> <given-names>HF</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Vascular hyperpermeability, angiogenesis, and stroma generation</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>2</volume><elocation-id>a006544</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a006544</pub-id><pub-id pub-id-type="pmid">22355795</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishijima</surname> <given-names>K</given-names></name><name><surname>Ng</surname> <given-names>YS</given-names></name><name><surname>Zhong</surname> <given-names>L</given-names></name><name><surname>Bradley</surname> <given-names>J</given-names></name><name><surname>Schubert</surname> <given-names>W</given-names></name><name><surname>Jo</surname> <given-names>N</given-names></name><name><surname>Akita</surname> <given-names>J</given-names></name><name><surname>Samuelsson</surname> <given-names>SJ</given-names></name><name><surname>Robinson</surname> <given-names>GS</given-names></name><name><surname>Adamis</surname> <given-names>AP</given-names></name><name><surname>Shima</surname> <given-names>DT</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury</article-title><source>The American Journal of Pathology</source><volume>171</volume><fpage>53</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.2353/ajpath.2007.061237</pub-id><pub-id pub-id-type="pmid">17591953</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opatrilova</surname> <given-names>R</given-names></name><name><surname>Kubatka</surname> <given-names>P</given-names></name><name><surname>Caprnda</surname> <given-names>M</given-names></name><name><surname>Büsselberg</surname> <given-names>D</given-names></name><name><surname>Krasnik</surname> <given-names>V</given-names></name><name><surname>Vesely</surname> <given-names>P</given-names></name><name><surname>Saxena</surname> <given-names>S</given-names></name><name><surname>Ruia</surname> <given-names>S</given-names></name><name><surname>Mozos</surname> <given-names>I</given-names></name><name><surname>Rodrigo</surname> <given-names>L</given-names></name><name><surname>Kruzliak</surname> <given-names>P</given-names></name><name><surname>Dos Santos</surname> <given-names>KG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Nitric oxide in the pathophysiology of retinopathy: evidences from preclinical and clinical researches</article-title><source>Acta Ophthalmologica</source><volume>96</volume><fpage>222</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1111/aos.13384</pub-id><pub-id pub-id-type="pmid">28391624</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orsenigo</surname> <given-names>F</given-names></name><name><surname>Giampietro</surname> <given-names>C</given-names></name><name><surname>Ferrari</surname> <given-names>A</given-names></name><name><surname>Corada</surname> <given-names>M</given-names></name><name><surname>Galaup</surname> <given-names>A</given-names></name><name><surname>Sigismund</surname> <given-names>S</given-names></name><name><surname>Ristagno</surname> <given-names>G</given-names></name><name><surname>Maddaluno</surname> <given-names>L</given-names></name><name><surname>Koh</surname> <given-names>GY</given-names></name><name><surname>Franco</surname> <given-names>D</given-names></name><name><surname>Kurtcuoglu</surname> <given-names>V</given-names></name><name><surname>Poulikakos</surname> <given-names>D</given-names></name><name><surname>Baluk</surname> <given-names>P</given-names></name><name><surname>McDonald</surname> <given-names>D</given-names></name><name><surname>Grazia Lampugnani</surname> <given-names>M</given-names></name><name><surname>Dejana</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Phosphorylation of VE-cadherin is modulated by haemodynamic forces and contributes to the regulation of vascular permeability in vivo</article-title><source>Nature Communications</source><volume>3</volume><elocation-id>1208</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms2199</pub-id><pub-id pub-id-type="pmid">23169049</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname> <given-names>A</given-names></name><name><surname>Cholkar</surname> <given-names>K</given-names></name><name><surname>Agrahari</surname> <given-names>V</given-names></name><name><surname>Mitra</surname> <given-names>AK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Ocular drug delivery systems: an overview</article-title><source>World Journal of Pharmacology</source><volume>2</volume><fpage>47</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.5497/wjp.v2.i2.47</pub-id><pub-id pub-id-type="pmid">25590022</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prahst</surname> <given-names>C</given-names></name><name><surname>Ashrafzadeh</surname> <given-names>P</given-names></name><name><surname>Mead</surname> <given-names>T</given-names></name><name><surname>Figueiredo</surname> <given-names>A</given-names></name><name><surname>Chang</surname> <given-names>K</given-names></name><name><surname>Richardson</surname> <given-names>D</given-names></name><name><surname>Venkaraman</surname> <given-names>L</given-names></name><name><surname>Richards</surname> <given-names>M</given-names></name><name><surname>Russo</surname> <given-names>AM</given-names></name><name><surname>Harrington</surname> <given-names>K</given-names></name><name><surname>Ouarné</surname> <given-names>M</given-names></name><name><surname>Pena</surname> <given-names>A</given-names></name><name><surname>Chen</surname> <given-names>DF</given-names></name><name><surname>Claesson-Welsh</surname> <given-names>L</given-names></name><name><surname>Cho</surname> <given-names>KS</given-names></name><name><surname>Franco</surname> <given-names>CA</given-names></name><name><surname>Bentley</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mouse retinal cell behaviour in space and time using light sheet fluorescence microscopy</article-title><source>eLife</source><volume>9</volume><elocation-id>e49779</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.49779</pub-id><pub-id pub-id-type="pmid">32073398</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname> <given-names>MA</given-names></name><name><surname>Senga</surname> <given-names>T</given-names></name><name><surname>Ito</surname> <given-names>S</given-names></name><name><surname>Hyodo</surname> <given-names>T</given-names></name><name><surname>Hasegawa</surname> <given-names>H</given-names></name><name><surname>Hamaguchi</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>S-Nitrosylation at cysteine 498 of c-Src tyrosine kinase regulates nitric Oxide-mediated cell invasion</article-title><source>Journal of Biological Chemistry</source><volume>285</volume><fpage>3806</fpage><lpage>3814</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.059782</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname> <given-names>MO</given-names></name><name><surname>Antunes</surname> <given-names>E</given-names></name><name><surname>de Nucci</surname> <given-names>G</given-names></name><name><surname>Lovisolo</surname> <given-names>SM</given-names></name><name><surname>Zatz</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Chronic inhibition of nitric oxide synthesis A new model of arterial hypertension</article-title><source>Hypertension</source><volume>20</volume><fpage>298</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.20.3.298</pub-id><pub-id pub-id-type="pmid">1516948</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname> <given-names>I</given-names></name><name><surname>Obata</surname> <given-names>Y</given-names></name><name><surname>Kasahara</surname> <given-names>K</given-names></name><name><surname>Nakayama</surname> <given-names>Y</given-names></name><name><surname>Fukumoto</surname> <given-names>Y</given-names></name><name><surname>Yamasaki</surname> <given-names>T</given-names></name><name><surname>Yokoyama</surname> <given-names>KK</given-names></name><name><surname>Saito</surname> <given-names>T</given-names></name><name><surname>Yamaguchi</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Differential trafficking of src, lyn, yes and fyn is specified by the state of palmitoylation in the SH4 domain</article-title><source>Journal of Cell Science</source><volume>122</volume><fpage>965</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1242/jcs.034843</pub-id><pub-id pub-id-type="pmid">19258394</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schleicher</surname> <given-names>M</given-names></name><name><surname>Yu</surname> <given-names>J</given-names></name><name><surname>Murata</surname> <given-names>T</given-names></name><name><surname>Derakhshan</surname> <given-names>B</given-names></name><name><surname>Atochin</surname> <given-names>D</given-names></name><name><surname>Qian</surname> <given-names>L</given-names></name><name><surname>Kashiwagi</surname> <given-names>S</given-names></name><name><surname>Di Lorenzo</surname> <given-names>A</given-names></name><name><surname>Harrison</surname> <given-names>KD</given-names></name><name><surname>Huang</surname> <given-names>PL</given-names></name><name><surname>Sessa</surname> <given-names>WC</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The Akt1-eNOS Axis illustrates the specificity of kinase-substrate relationships in vivo</article-title><source>Science Signaling</source><volume>2</volume><elocation-id>ra41</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2000343</pub-id><pub-id pub-id-type="pmid">19654415</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname> <given-names>A</given-names></name><name><surname>Fruttiger</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Oxygen-induced retinopathy: a model for vascular pathology in the retina</article-title><source>Eye</source><volume>24</volume><fpage>416</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/eye.2009.306</pub-id><pub-id pub-id-type="pmid">20010791</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semenza</surname> <given-names>GL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Hypoxia-inducible factors in physiology and medicine</article-title><source>Cell</source><volume>148</volume><fpage>399</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.01.021</pub-id><pub-id pub-id-type="pmid">22304911</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sessa</surname> <given-names>WC</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>eNOS at a glance</article-title><source>Journal of Cell Science</source><volume>117</volume><fpage>2427</fpage><lpage>2429</lpage><pub-id pub-id-type="doi">10.1242/jcs.01165</pub-id><pub-id pub-id-type="pmid">15159447</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simko</surname> <given-names>F</given-names></name><name><surname>Baka</surname> <given-names>T</given-names></name><name><surname>Krajcirovicova</surname> <given-names>K</given-names></name><name><surname>Repova</surname> <given-names>K</given-names></name><name><surname>Aziriova</surname> <given-names>S</given-names></name><name><surname>Zorad</surname> <given-names>S</given-names></name><name><surname>Poglitsch</surname> <given-names>M</given-names></name><name><surname>Adamcova</surname> <given-names>M</given-names></name><name><surname>Reiter</surname> <given-names>R</given-names></name><name><surname>Paulis</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Effect of melatonin on the Renin-Angiotensin-Aldosterone system in l-NAME-Induced hypertension</article-title><source>Molecules</source><volume>23</volume><elocation-id>265</elocation-id><pub-id pub-id-type="doi">10.3390/molecules23020265</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>LE</given-names></name><name><surname>Wesolowski</surname> <given-names>E</given-names></name><name><surname>McLellan</surname> <given-names>A</given-names></name><name><surname>Kostyk</surname> <given-names>SK</given-names></name><name><surname>D'Amato</surname> <given-names>R</given-names></name><name><surname>Sullivan</surname> <given-names>R</given-names></name><name><surname>D'Amore</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Oxygen-induced retinopathy in the mouse</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>35</volume><fpage>101</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">7507904</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>RO</given-names></name><name><surname>Ninchoji</surname> <given-names>T</given-names></name><name><surname>Gordon</surname> <given-names>E</given-names></name><name><surname>André</surname> <given-names>H</given-names></name><name><surname>Dejana</surname> <given-names>E</given-names></name><name><surname>Vestweber</surname> <given-names>D</given-names></name><name><surname>Kvanta</surname> <given-names>A</given-names></name><name><surname>Claesson-Welsh</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin</article-title><source>eLife</source><volume>9</volume><elocation-id>e54056</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.54056</pub-id><pub-id pub-id-type="pmid">32312382</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Söderberg</surname> <given-names>O</given-names></name><name><surname>Gullberg</surname> <given-names>M</given-names></name><name><surname>Jarvius</surname> <given-names>M</given-names></name><name><surname>Ridderstråle</surname> <given-names>K</given-names></name><name><surname>Leuchowius</surname> <given-names>KJ</given-names></name><name><surname>Jarvius</surname> <given-names>J</given-names></name><name><surname>Wester</surname> <given-names>K</given-names></name><name><surname>Hydbring</surname> <given-names>P</given-names></name><name><surname>Bahram</surname> <given-names>F</given-names></name><name><surname>Larsson</surname> <given-names>LG</given-names></name><name><surname>Landegren</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Direct observation of individual endogenous protein complexes in situ by proximity ligation</article-title><source>Nature Methods</source><volume>3</volume><fpage>995</fpage><lpage>1000</lpage><pub-id pub-id-type="doi">10.1038/nmeth947</pub-id><pub-id pub-id-type="pmid">17072308</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surks</surname> <given-names>HK</given-names></name><name><surname>Mochizuki</surname> <given-names>N</given-names></name><name><surname>Kasai</surname> <given-names>Y</given-names></name><name><surname>Georgescu</surname> <given-names>SP</given-names></name><name><surname>Tang</surname> <given-names>KM</given-names></name><name><surname>Ito</surname> <given-names>M</given-names></name><name><surname>Lincoln</surname> <given-names>TM</given-names></name><name><surname>Mendelsohn</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Regulation of myosin phosphatase by a specific interaction with cGMP- dependent protein kinase ialpha</article-title><source>Science</source><volume>286</volume><fpage>1583</fpage><lpage>1587</lpage><pub-id pub-id-type="doi">10.1126/science.286.5444.1583</pub-id><pub-id pub-id-type="pmid">10567269</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Testini</surname> <given-names>C</given-names></name><name><surname>Smith</surname> <given-names>RO</given-names></name><name><surname>Jin</surname> <given-names>Y</given-names></name><name><surname>Martinsson</surname> <given-names>P</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Hedlund</surname> <given-names>M</given-names></name><name><surname>Sáinz-Jaspeado</surname> <given-names>M</given-names></name><name><surname>Shibuya</surname> <given-names>M</given-names></name><name><surname>Hellström</surname> <given-names>M</given-names></name><name><surname>Claesson-Welsh</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Myc-dependent endothelial proliferation is controlled by phosphotyrosine 1212 in VEGF receptor-2</article-title><source>EMBO Reports</source><volume>20</volume><elocation-id>e47845</elocation-id><pub-id pub-id-type="doi">10.15252/embr.201947845</pub-id><pub-id pub-id-type="pmid">31545012</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thoonen</surname> <given-names>R</given-names></name><name><surname>Sips</surname> <given-names>PY</given-names></name><name><surname>Bloch</surname> <given-names>KD</given-names></name><name><surname>Buys</surname> <given-names>ES</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Pathophysiology of hypertension in the absence of nitric oxide/cyclic GMP signaling</article-title><source>Current Hypertension Reports</source><volume>15</volume><fpage>47</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1007/s11906-012-0320-5</pub-id><pub-id pub-id-type="pmid">23233080</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thors</surname> <given-names>B</given-names></name><name><surname>Halldórsson</surname> <given-names>H</given-names></name><name><surname>Thorgeirsson</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Thrombin and histamine stimulate endothelial nitric-oxide synthase phosphorylation at Ser1177 via an AMPK mediated pathway independent of PI3K-Akt</article-title><source>FEBS Letters</source><volume>573</volume><fpage>175</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2004.07.078</pub-id><pub-id pub-id-type="pmid">15327994</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vrankova</surname> <given-names>S</given-names></name><name><surname>Zemancikova</surname> <given-names>A</given-names></name><name><surname>Torok</surname> <given-names>J</given-names></name><name><surname>Pechanova</surname> <given-names>O</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Effect of low dose L-NAME pretreatment on nitric oxide/reactive oxygen species balance and vasoactivity in L-NAME/salt-induced hypertensive rats</article-title><source>Journal of Physiology and Pharmacology </source><volume>70</volume><elocation-id>5</elocation-id><pub-id pub-id-type="doi">10.26402/jpp.2019.4.05</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallez</surname> <given-names>Y</given-names></name><name><surname>Cand</surname> <given-names>F</given-names></name><name><surname>Cruzalegui</surname> <given-names>F</given-names></name><name><surname>Wernstedt</surname> <given-names>C</given-names></name><name><surname>Souchelnytskyi</surname> <given-names>S</given-names></name><name><surname>Vilgrain</surname> <given-names>I</given-names></name><name><surname>Huber</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site</article-title><source>Oncogene</source><volume>26</volume><fpage>1067</fpage><lpage>1077</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209855</pub-id><pub-id pub-id-type="pmid">16909109</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wessel</surname> <given-names>F</given-names></name><name><surname>Winderlich</surname> <given-names>M</given-names></name><name><surname>Holm</surname> <given-names>M</given-names></name><name><surname>Frye</surname> <given-names>M</given-names></name><name><surname>Rivera-Galdos</surname> <given-names>R</given-names></name><name><surname>Vockel</surname> <given-names>M</given-names></name><name><surname>Linnepe</surname> <given-names>R</given-names></name><name><surname>Ipe</surname> <given-names>U</given-names></name><name><surname>Stadtmann</surname> <given-names>A</given-names></name><name><surname>Zarbock</surname> <given-names>A</given-names></name><name><surname>Nottebaum</surname> <given-names>AF</given-names></name><name><surname>Vestweber</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Leukocyte extravasation and vascular permeability are each controlled in vivo by different tyrosine residues of VE-cadherin</article-title><source>Nature Immunology</source><volume>15</volume><fpage>223</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1038/ni.2824</pub-id><pub-id pub-id-type="pmid">24487320</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanfolin</surname> <given-names>M</given-names></name><name><surname>Faro</surname> <given-names>R</given-names></name><name><surname>Araujo</surname> <given-names>EG</given-names></name><name><surname>Guaraldo</surname> <given-names>AM</given-names></name><name><surname>Antunes</surname> <given-names>E</given-names></name><name><surname>De Nucci</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats</article-title><source>Journal of Cardiovascular Pharmacology</source><volume>47</volume><fpage>391</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1097/00004872-200402001-00254</pub-id><pub-id pub-id-type="pmid">16633081</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>Z</given-names></name><name><surname>Nelson</surname> <given-names>AR</given-names></name><name><surname>Betsholtz</surname> <given-names>C</given-names></name><name><surname>Zlokovic</surname> <given-names>BV</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Establishment and dysfunction of the Blood-Brain barrier</article-title><source>Cell</source><volume>163</volume><fpage>1064</fpage><lpage>1078</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.10.067</pub-id><pub-id pub-id-type="pmid">26590417</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.64944.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Koh</surname><given-names>Gou Young</given-names></name><role>Reviewing Editor</role><aff><institution>Institute of Basic Science and Korea Advanced Institute of Science and Technology (KAIST)</institution><country>Republic of Korea</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Koh</surname><given-names>Gou Young</given-names> </name><role>Reviewer</role><aff><institution>Institute of Basic Science and Korea Advanced Institute of Science and Technology (KAIST)</institution><country>Republic of Korea</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The strength of this study is to clarify the roles of eNOS in ischemic neovascularization and vessel permeability using an oxygen-induced retinopathy (OIR) mouse model. It shows that either systemic NO formation inhibitor L-NMMA or eNOS (S1176A) mutant causes reduced retinal vascular tuft formation, and also reduces vascular leakage by stabilizing VE-cadherin in a c-Src-dependent manner. It also shows that a single dose of L-NMMA restores the vascular barrier and prevents leakage. Based on these findings, they have concluded that eNOS induces destabilization of adherens junctions and vascular hyperpermeability by converging with the VEGFA/VEGFR2/c43 Src/VE-cadherin pathway and that this pathway can be selectively inhibited by blocking NO formation. This study is well-designed and well-presented, and mechanistically solid.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;eNOS-induced vascular barrier disruption in retinopathy by c-Src activation and tyrosine phosphorylation of VE-cadherin&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, including Gou Young Koh as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Didier Stainier as the Senior Editor.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our policy on revisions we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, when editors judge that a submitted work as a whole belongs in <italic>eLife</italic> but that some conclusions require a modest amount of additional new data, as they do with your paper, we are asking that the manuscript be revised to either limit claims to those supported by data in hand, or to explicitly state that the relevant conclusions require additional supporting data.</p><p>Our expectation is that the authors will eventually carry out the additional experiments and report on how they affect the relevant conclusions either in a preprint on bioRxiv or medRxiv, or if appropriate, as a Research Advance in <italic>eLife</italic>, either of which would be linked to the original paper.</p><p>The comments of all two reviewers are in good agreement. While the reviewers found this study is well-designed and well-presented, mechanistically solid, and to be of importance as a translational research, they raised concerns about the limitation to be generalized to apply major ocular diseases including wet-AMD and diabetic retinopathy and the inconsistencies of the results and interpretations to the previous reports. The authors are required to carefully address the comments point-by-point in a data-driven manner or with further analyses or discussions. Specifically, the authors are encouraged to pay attention to the major comments 2 and 3 of reviewer 1 and comments 1 and 2 of reviewer 2. If necessary, please provide the reasons for not implementing the suggested changes.</p><p><italic>Reviewer #1:</italic></p><p>This study has elegantly clarified the role of eNOS in ischemic neovascularization and vessel permeability using an oxygen-induced retinopathy (OIR) mouse model. The authors show that either systemic NO formation inhibitor L-NMMA or eNOS (S1176A) mutant causes reduced retinal vascular tuft formation, and also reduces vascular leakage by stabilizing VE-cadherin in a c-Src-dependent manner. Because the OIR model can reflect only &quot;retinopathy of prematurity&quot; in premature newborns but cannot fully reflect wet-AMD (in fact, choroidal vessel disease) and diabetic retinopathy in adult, this study has a limitation to be generalized to apply major ocular diseases including wet-AMD and diabetic retinopathy. Nevertheless, this study is well-designed and well-presented, and mechanistically solid, and thus it deserves to be published in <italic>eLife</italic>.</p><p>The study conducted by Ninchoji et al. has clarified the role of eNOS in ischemic neovascularization and vessel permeability using an oxygen-induced retinopathy (OIR) mouse model. They show that either systemic NO formation inhibitor L-NMMA or eNOS (S1176A) mutant causes reduced retinal vascular tuft formation, and also reduces vascular leakage by stabilizing VE-cadherin in a c-Src-dependent manner. They also show that a single dose of L-NMMA restores the vascular barrier and prevents leakage. Based on these findings, they have concluded that eNOS induces destabilization of adherens junctions and vascular hyperpermeability by converging with the VEGFA/VEGFR2/c43 Src/VE-cadherin pathway and that this pathway can be selectively inhibited by blocking NO formation. This study is well-designed and well-presented, and mechanistically solid. However, the following comments need to be appropriately addressed:</p><p>1. The OIR model can reflect &quot;retinopathy of prematurity&quot; in premature newborns but cannot fully reflect wet-AMD (in fact, choroidal vessel disease) and diabetic retinopathy in adult. Therefore, the authors need to tone down the generalization and limit the applicability.</p><p>2. Pericyte dropout and infiltration of macrophages are critical components to vascular leakage in the OIR model, as shown in recent papers (Park et al., Nature Communication, 2017; Ogura et al., JCI Insight 2017; Omori et al., JCI Insight 2018). What are the changes in PC-EC coupling and macrophage infiltration in either L-NMMA treatment or eNOS(S1176A) mutant by OIR.</p><p>3. Because the vascular tuft and deformed vessels formed by OIR have generally no circulation, it causes severe hypoxia or anoxia to the retinal neurons. Is there restoration in the retinal circulation after L-NMMA treatment? It can be measured by a lectin perfusion assay.</p><p>4. Restoration of functional blood vessels in the avascular area is the most important point for treating the patients of &quot;retinopathy of prematurity&quot;. In this regard, single treatment of NMMA is not sufficient. Therefore, the description of this therapeutic option needs to be further defined.</p><p><italic>Reviewer #3:</italic></p><p>Ninchoji T. et al. demonstrated the signaling cascade that worsens the endothelial cell (EC) barrier function by phosphorylating vascular endothelial cadherin (VE-cadherin). The effect of endothelial NO synthetase (eNOS, Nos3) on barrier function has been different in different vessel types and in different disease models. In addition, it is also controversial whether c-Src is upstream or downstream of eNOS. The authors delineate the signaling cascade that regulates retinal barrier function using the mice (genetically mutated Nos3 (S1176A) that cannot be phosphorylated) and the mice (VEC-Y685F) in which VE-cadherin cannot be phosphorylated in oxygen-induced retinopathy (OIR) model.</p><p>The authors extended their previous results reported in <italic>eLife</italic> (Smith et al. <italic>eLife</italic> 2020;9: e54056) to show the VEGF-dependent vascular leakage in OIR model. Previously, they reported that phosphorylation of VE-cadherin Y685 results in vessel leakage. In the present study, they analyzed Tuft area and avascular area similarly to the previous report and delineated the VEGF/VEGFR2-dependent signaling that causes vascular leakage. In the mice in which Nos3S1176A was knocked-in, vascular leakage was suppressed. Moreover, VEC-Y685F mutant mice showed less tuft area than wildtype. This is consistent with their previous result. The reduction in tuft area was comparable in PBS and L-NMMA-treated Y685F mouse retinas and that seen in L-NMMA-treated wildtype mice. The involvement of C-Src downstream of VEGF/VEGFR2-eNOS was shown in proximity ligation assay (PLA). Collectively, they delineate the signaling mediated by VEGF/VEGFR2-eNOS (S1176 phosphorylation)-c-Src (Y418 phosphorylation)-VE-cad(Y685 phosphorylation) that induces leakage in OIR model.</p><p>The signaling cascade is proven by the two different knock-iin mice (Nos3 S1176A and VEC Y685F) in the established OIR model in vivo, while other groups show eNOS-dependent barrier stabilization effect on ECs in different model.</p><p>1. Involvement of c-Src in OIR</p><p>There is one inconsistency in the model illustrated in Figure 6. In the previous report by Smith (the same group), the authors mentioned that pY949 is VEGFR2 appeared not to contribute to regulation of c-Src kinase activity in the retina vasculature. However, the model in Figure 6 clearly points to the Y949 of VEGFR2 and c-Src Y418. Considering the previous results and the new results, the authors need to revise the involvement of c-Src in OIR model Immunoblot analyses of in vitro assay using human retinal microvascular endothelial cells might help the readers to understand the upstream and downstream of VEGFR2; namely AKT-eNOS-c-Src and another direct c-Src-mediated VE-cad phosphorylation by showing time course of phosphorylation of Akt and eNOS. In addition to this, c-Src phosphorylation might be analyzed in a time-dependent manner, although Fyn or Yes might be similarly phosphorylated. At least, time course can be analyzed.</p><p>2. Anti-VEGF therapy</p><p>The authors describe the disadvantage of anti-VEGF therapy in the introduction. However, the vascular leakage in OIR is dependent on VEGF/VEGFR2 as illustrated in Figure 6. Why is anti-VEGF therapy ineffective in OIR? VEGF-dependent eNOS activation should be inhibited by ant-VEGF therapy. Because L-NMMA might become a potential candidate as an ant-eNOS therapy, the authors had better mention the usefulness of this as an alternative or additional therapy for retinopathy.</p><p>3. The intensity of red in Figure 2 -supplement figure 2c is too low. These panels should be replaced.</p><p>4. L-NMMA should be explained when it appears first in page 9 instead of page 11</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.64944.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>This study has elegantly clarified the role of eNOS in ischemic neovascularization and vessel permeability using an oxygen-induced retinopathy (OIR) mouse model. The authors show that either systemic NO formation inhibitor L-NMMA or eNOS (S1176A) mutant causes reduced retinal vascular tuft formation, and also reduces vascular leakage by stabilizing VE-cadherin in a c-Src-dependent manner. Because the OIR model can reflect only &quot;retinopathy of prematurity&quot; in premature newborns but cannot fully reflect wet-AMD (in fact, choroidal vessel disease) and diabetic retinopathy in adult, this study has a limitation to be generalized to apply major ocular diseases including wet-AMD and diabetic retinopathy. Nevertheless, this study is well-designed and well-presented, and mechanistically solid, and thus it deserves to be published in eLife.</p><p>The study conducted by Ninchoji et al. has clarified the role of eNOS in ischemic neovascularization and vessel permeability using an oxygen-induced retinopathy (OIR) mouse model. They show that either systemic NO formation inhibitor L-NMMA or eNOS (S1176A) mutant causes reduced retinal vascular tuft formation, and also reduces vascular leakage by stabilizing VE-cadherin in a c-Src-dependent manner. They also show that a single dose of L-NMMA restores the vascular barrier and prevents leakage. Based on these findings, they have concluded that eNOS induces destabilization of adherens junctions and vascular hyperpermeability by converging with the VEGFA/VEGFR2/c43 Src/VE-cadherin pathway and that this pathway can be selectively inhibited by blocking NO formation. This study is well-designed and well-presented, and mechanistically solid. However, the following comments need to be appropriately addressed:</p><p>1. The OIR model can reflect &quot;retinopathy of prematurity&quot; in premature newborns but cannot fully reflect wet-AMD (in fact, choroidal vessel disease) and diabetic retinopathy in adult. Therefore, the authors need to tone down the generalization and limit the applicability.</p></disp-quote><p>We thank the reviewer for the appreciative comments. We concur with the reviewer’s description of the limitation of the OIR model and have toned down the generalization and applicability. See track changes in the discussion, lines 664-666, 675-679.</p><disp-quote content-type="editor-comment"><p>2. Pericyte dropout and infiltration of macrophages are critical components to vascular leakage in the OIR model, as shown in recent papers (Park et al., Nature Communication, 2017; Ogura et al., JCI Insight 2017; Omori et al., JCI Insight 2018). What are the changes in PC-EC coupling and macrophage infiltration in either L-NMMA treatment or eNOS(S1176A) mutant by OIR.</p></disp-quote><p>We have now performed new experiments and measured NG2-positive pericyte coating and the presence of CD68-positive macrophages in retinas after OIRchallenge of wildtype or <italic>Nos3<sup>S1176A/Nos3S1176A</sup></italic> mutant mice, as well as mice treated with multiple or single dose of L-NMMA. The extent of pericyte coating and macrophage infiltration was the same in all conditions. These data are now shown in Figure 1—figure supplement 3, Figure 4—figure supplement 1 and Figure 5—figure supplement 1.</p><disp-quote content-type="editor-comment"><p>3. Because the vascular tuft and deformed vessels formed by OIR have generally no circulation, it causes severe hypoxia or anoxia to the retinal neurons. Is there restoration in the retinal circulation after L-NMMA treatment? It can be measured by a lectin perfusion assay.</p></disp-quote><p>We have now performed perfusion using fluorescent lectin and although perfusion is increased in tufts formed in the <italic>Nos3<sup>S1176A/Nos3S1176A</sup></italic> mutant mice, there was no change in perfusion of tufts formed after multiple or single-dose treatment with L-NMMA (see Figure 4—figure supplement 1 and Figure 5—figure supplement 1). We have added a comment on the lack of improved perfusion in the discussion, lines 625-628.</p><disp-quote content-type="editor-comment"><p>4. Restoration of functional blood vessels in the avascular area is the most important point for treating the patients of &quot;retinopathy of prematurity&quot;. In this regard, single treatment of NMMA is not sufficient. Therefore, the description of this therapeutic option needs to be further defined.</p></disp-quote><p>We thank the reviewer for this comment and we of course agree. The single-dose treatment was a useful strategy in distinguishing the effects of the LNMMA treatment on tuft formation (which was unchanged with the single dose) and leakage (which was suppressed). The clinical implication of the L-NMMA treatment we agree was overemphasized and has now been toned down throughout.</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>Ninchoji T. et al. demonstrated the signaling cascade that worsens the endothelial cell (EC) barrier function by phosphorylating vascular endothelial cadherin (VE-cadherin). The effect of endothelial NO synthetase (eNOS, Nos3) on barrier function has been different in different vessel types and in different disease models. In addition, it is also controversial whether c-Src is upstream or downstream of eNOS. The authors delineate the signaling cascade that regulates retinal barrier function using the mice (genetically mutated Nos3 (S1176A) that cannot be phosphorylated) and the mice (VEC-Y685F) in which VE-cadherin cannot be phosphorylated in oxygen-induced retinopathy (OIR) model.</p><p>The authors extended their previous results reported in eLife (Smith et al. eLife 2020;9: e54056) to show the VEGF-dependent vascular leakage in OIR model. Previously, they reported that phosphorylation of VE-cadherin Y685 results in vessel leakage. In the present study, they analyzed Tuft area and avascular area similarly to the previous report and delineated the VEGF/VEGFR2-dependent signaling that causes vascular leakage. In the mice in which Nos3S1176A was knocked-in, vascular leakage was suppressed. Moreover, VEC-Y685F mutant mice showed less tuft area than wildtype. This is consistent with their previous result. The reduction in tuft area was comparable in PBS and L-NMMA-treated Y685F mouse retinas and that seen in L-NMMA-treated wildtype mice. The involvement of C-Src downstream of VEGF/VEGFR2-eNOS was shown in proximity ligation assay (PLA). Collectively, they delineate the signaling mediated by VEGF/VEGFR2-eNOS (S1176 phosphorylation)-c-Src (Y418 phosphorylation)-VE-cad(Y685 phosphorylation) that induces leakage in OIR model.</p><p>The signaling cascade is proven by the two different knock-iin mice (Nos3 S1176A and VEC Y685F) in the established OIR model in vivo, while other groups show eNOS-dependent barrier stabilization effect on ECs in different model.</p><p>1. Involvement of c-Src in OIR</p><p>There is one inconsistency in the model illustrated in Figure 6. In the previous report by Smith (the same group), the authors mentioned that pY949 is VEGFR2 appeared not to contribute to regulation of c-Src kinase activity in the retina vasculature. However, the model in Figure 6 clearly points to the Y949 of VEGFR2 and c-Src Y418. Considering the previous results and the new results, the authors need to revise the involvement of c-Src in OIR model Immunoblot analyses of in vitro assay using human retinal microvascular endothelial cells might help the readers to understand the upstream and downstream of VEGFR2; namely AKT-eNOS-c-Src and another direct c-Src-mediated VE-cad phosphorylation by showing time course of phosphorylation of Akt and eNOS. In addition to this, c-Src phosphorylation might be analyzed in a time-dependent manner, although Fyn or Yes might be similarly phosphorylated. At least, time course can be analyzed.</p></disp-quote><p>We have followed the reviewer’s suggestion and now provide a time course where the effects of L-NMMA treatment on VEGFA-induced phosphorylation of eNOS, AKT, VE-cadherin and Src have been examined (see Figure 2 – suppl figure 1, lines 452-464). Interestingly, VEGFA induces a biphasic pY418 signal and one of them, the second peak, is inhibited by L-NMMA. We suggest that the different peaks may represent activation of different Src family kinases as the pY418 antibody does not distinguish between c-Src, Yes and Fyn. We therefore would like to keep the PLA results, which allows a firm conclusion on the effect of L-NMMA specifically on c-Src activation. Of note, a PLA signal will be generated when the secondary antibodies detect the primary antibodies (against c-Src protein and against pY418) in close proximity, i.e. when c-Src is phosphorylated on Y418. We have gone through the text and figures to ensure we have described this clearly, for example in Figure 4C, which was erroneously labeled before. We apologize for this oversight.</p><p>Taken together, we are not yet ready to revise the involvement of c-Src in the OIR model as the PLA results show activation of c-Src in an eNOS dependent manner at endothelial junctions. To bring this further, we need even more refined tools. Indeed, detailed analyses of the specific biological roles of Src, Yes and Fyn in endothelial cell-specific deletion mouse models have been initiated in our group, but these are challenging projects in their own rights.</p><disp-quote content-type="editor-comment"><p>2. Anti-VEGF therapy</p><p>The authors describe the disadvantage of anti-VEGF therapy in the introduction. However, the vascular leakage in OIR is dependent on VEGF/VEGFR2 as illustrated in Figure 6. Why is anti-VEGF therapy ineffective in OIR? VEGF-dependent eNOS activation should be inhibited by ant-VEGF therapy. Because L-NMMA might become a potential candidate as an ant-eNOS therapy, the authors had better mention the usefulness of this as an alternative or additional therapy for retinopathy.</p></disp-quote><p>The standard clinical treatment by now is anti-VEGF therapy and we describe the limitation of this therapy in the introduction. The problem is not necessarily that it is ineffective but rather that it has side effects by targeting VEGFR2 on endothelial cells as well as on neurons. See Introduction, lines 77-83. As suggested by Reviewer 1, we have now toned down the clinical perspective which we agree was overemphasized. However, please see the discussion, lines 672-673, where the potential usefulness of combinatorial treatment with anti-VEGF and NO suppressive drugs was already mentioned.</p><disp-quote content-type="editor-comment"><p>3. The intensity of red in Figure 2 -supplement figure 2c is too low. These panels should be replaced.</p></disp-quote><p>Figure 2 -suppl figure 2c show the PLA controls and these were negative – no signal. The images are representative and have been kept.</p><disp-quote content-type="editor-comment"><p>4. L-NMMA should be explained when it appears first in page 9 instead of page 11</p></disp-quote><p>Amended.</p></body></sub-article></article>